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INTRODUCTION
NANOPARTICLES:
To obtain a desirable therapeutic response, the correct amount of the drug should be
transported and delivered to  the site  of action.  The distribution to other  tissues  therefore
seems to be a potential cause for toxicity. Targeted drug delivery system involves a number of
essential bio ligands for bio signalling and physiological cell need. They are operated through
bio ports which are referred as receptors. The ligand-receptor interactions are highly stereo
specific. Therefore ligands or receptors could be exploited for cell specific drug delivery.
Table 1: CARRIER SYSTEMS USED FOR TARGETED DRUG DELIVERY:
S.No                        Category                            Example
   1 Colloidal carriers a) Vesicular systems
Niosomes,liposomes,virosomes,
pharmacosomes, immune liposomes
b) Micro particulate systems
Nanoparticles,microparticles,nanocapsules,
magnetic  microspheres,  albumin
microspheres.
   2 Cellular carriers        Resealed  erythrocytes,  antibodies,  serum
albumin,               platelets and leukocytes.
   3 Supra  molecular  delivery
systems
        Micelles, mixed micelles, reverse micelles,
polymeric  micelles,  lipoproteins,  liquid  crystals,
synthetic LDL.
  4 Polymer based systems          Mucoadhesive, biodegradable, signal sensitive,
bio erodible.
  5 Macromolecular carriers a) Proteins,  glycoprotein,  neo  glycoproteins,
artificial viral envelopes.
b) Glycosylated water soluble polymers (poly-
lysine).
c) Mabs, antibody enzyme complex.
d) Toxins,  immunotoxin  and  rCD4  toxin
conjugates.
e) Lectins and polysaccharides.
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COLLOIDAL DRUG CARRIER SYSTEM:
The colloidal carriers based on biodegradable and biocompatible polymeric systems
have largely influenced the controlled and targeted drug delivery concepts. Nanoparticles are
composed  of  synthetic  or  semi  synthetic  polymers.  Nanotechnology  is  the  study  of
nanoparticles,  nanosuspension,  nanoemulsion,  etc.,  Nanoparticle  is  a  collective  name  for
nanospheres and nanocapsules. Drugs absorbed at the surface, entrapped in the particle or
dissolved in it are called Nanospheres. The active substance dissolved in the inner core, or
absorbed at the surface is called nanocapsules.
             Nanosuspension consists of essentially pure drug and minimal quantities of surface
stabilizing agents; it provides sustained release at a level below the maximum tolerated dose
yet  at  its  therapeutically effective concentration.  They are mainly used for parentral  drug
delivery.
Table 2: VARIOUS CARRIER BASED DOSAGE FORMS:
S.NO CARRIER SYSTEM SIZE
RANGE
FEATURES METHOD  OF
PREPARATION
   1 Nanoparticles      
10-
1000nm
Submicron–sized
Colloidal
systems,biodegradable
(or) not
Emulsion
solvent
evaporation
method
   2 Solid lipid nanoparticle     
 50-
1000nm
Submicron  colloidal
carriers  containing
solid  hydrophobic core
having a  monolayer  of
phospholipids coating
High-pressure
homogenization
Micro  emulsion
formation
precipitation  as
lipid nanopellets
   3 Polymeric nanoparticles     10-
1000    nm
Sub-nanosized
colloidal  structure
composed  of  synthetic
or  semi  -synthetic
polymers
Nano
precipitation
method
   4 Lipid emulsion Lipid
globule
Multi  component  fluid
made  of  water.  A
o/w
w/o
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1 -100nm hydrophobic  liquid,  or
several  surfactants
resulting  in  a  stable
system
w/o/w
   5 Liposomes
25-100nm
Microscopic  vesicles
composed  of  one  or
more  concentric  lipid
bilayer,  separated  by
water or aqueous buffer
compartments 
Nano
precipitation
method
   6 Lipospheres    
    0.2-
100nm
Water  dispersible  solid
micro  particles
composed  of  solid
hydrophobic  fat  core
stabilized  by  a  mono
layers of phospholipids
molecules embedded in
a  micro  particles
surface
Melt  method
Co-solvent
method,  Pre
incorporation
into  lipophilic
carrier
   7 Lipid microtubles/
Micro cylinders 1nm
Self-organizing  system
in  which  surfactants
crystallize  into  tightly
packed  bilayers  that
spontaneously  form
cylinders
Self-
emulsification
   8 Ceramic nanoparticles
  50nm
Made  up  of  inorganic
(ceramic)  compounds
such  as  silica,  titania
and alumina
Emulsion
solvent
evaporation
method
   9 Functionalized
nanocarriers/quantum dots
Combination  of
functionalities  of
biomolecules  and nano
biologically  derived
molecular species
  10 Nanotubes and nanowires Self-assembling  sheet Chemical
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of  atoms  arranged  in
the  form  of  tubes  and
thread like structures of
nanoscale range
evaporation
dispersion
  11 Multi  composite  ultra  thin
capsules 50nm  few
micron
Molecular  assemblies
of  tailored  architecture
having  layer-by-layer
adsorption  of
oppositely  charged
macromolecules  on  to
colloidal particles
Langmuir-
Blodgett
technique  and
chemisorptions
from solution
12 Ethosomes Nanoinvasive  delivery
carriers  that  enable
drugs to reach the deep
skin  and  systemic
circulation
Ethanol
injection-
sonication
method
13 Niosomes 12-16
micron
Non-ionic  surfactant
vesicles  are  bi-layered
structures
Ether  injection
method.
14 Collidosomes Solid  microcapsules
which  are  hollow,
elastic shells
Self-assembly of
colloidal
particles  at  the
interface  of
emulsion
droplets
15 Pharmacosomes Pure  drug  vesicles
formed  by  the
amphiphilic drugs
16 Dendrimers Macromolecular
compounds  that
consists  of  a  series  of
branches  around  an
inner core
Polymerization
POLYMERIC NANOPARTCLES: 1, 2
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These  are  colloidal  particles  ranging  from  10-1000  nm  which  consist  of
macromolecular materials. This can be used therapeutically, e.g. as adjuvant in vaccines, drug
carriers  in  which  the  active  principle  (drug  or  biological  active  material)  is  dissolved,
entrapped  or  encapsulated.  The  active  principle  is  adsorbed  or  attached.  Polymeric
nanoparticles are composed of biodegradable or bio stable polymers and copolymers. The
active agents can be;
I. Entrapped or encapsulated within the particles
II. Physically adsorbed on surface (or)
III. Chemically linked to the surface of the nanoparticles.
POLYMERS USED IN THE PREPARATION OF POLYMERIC NANOPARTICLES:
Polymers used in manufacturing of polymeric nanoparticles are of two types;
1. Natural hydrophilic polymers (proteins and polysaccharides)
2. Synthetic hydrophobic polymers (poly lactic acid and PLGA)
Natural hydrophilic polymers:
Gelatin,  albumin,  vicilin  or  legumin  as  well  as  polysaccharides  like  agarose  or
alginates have been studied and characterized. These macromolecules are used due to their
intrinsic biodegradability and biocompatibility.
Synthetic hydrophobic polymers:
Polymers that are used for microsphere preparation are used for the preparation of
nanoparticle. Most of them are hydrophobic in nature. The polymers are either synthesized or
pre-polymerized during nanoparticles preparation.
PREPARATION TECHNIQUES OF NANOPARTICLES: 3, 4, 5.
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The preparation of nanoparticles depends on the physicochemical properties of the
polymer and the drug to be loaded. Two types of system with different inner structures are
apparently possible. They are:
1.  A matrix type system consisting of an entanglement of oligomer or polymer
units. (nanoparticles or nanospheres)
2. A reservoir  type  of  system  comprised  of  an  oily  core  surrounded  by  an
embryonic polymeric shell (nanocapsules)
The drug can be either entrapped within the reservoir or matrix or adsorbed on
the surface of these particulate systems. They are classified as;
Amphiphilic macromolecule cross-linking
• Heat cross linking
• Chemical cross-linking
Polymerization based methods
• Emulsion (micellar) polymerization
• Interfacial condensation polymerization
• Interfacial complexation 
• Polymerization of monomers insitu
• Dispersion polymerization
Polymer precipitation methods
• Solvent displacement (nanoprecipitation)
• Solvent extraction or evaporation
• Salting out
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FORMULATION  OF  NANOPARTICLE  USING  POLYMER  PRECIPITATION
METHOD: 6.
The hydrophobic polymer and hydrophobic drug is dissolved in an organic solvent. It
is  then  dispersed  in  a  continuous  aqueous  phase  in  which  the  polymer  is  insoluble.
Precipitation of the polymer produces nanoparticle with the drug loaded in it. 
Polymer precipitation is done by increasing the solubility of the organic solvent in the
external medium by adding alcohol.
 Solvent extraction method:
The  preparation  of  nanoparticles  begins  with  the  formation  of  conventional  O/W
emulsion between partially water miscible solvent containing the polymer and the drug, and
an  aqueous  phase  containing  stabilizer.  The  removal  of  the  solvent  (solvent  evaporation
method) or  addition of  water  to  diffuse the solvent  to  the external  phase (emulsification
diffusion method) is the two types of solvent extraction method.
Double emulsion solvent evaporation method:
Emulsion solvent evaporation method is modified and double emulsion of W/O/W
type has been used. Nanoparticles are formed by the evaporation of organic solvents. This is
then recovered by centrifugation, washed repeatedly with buffer and lyophilized.
Solvent displacement or nanoprecipitation:
This  method  is  based  on  the  interfacial  deposition  of  polymer  followed  by
displacement of a semi-polar solvent miscible with water from a lipophilic solution. This
method involves the use of an organic phase which is  completely soluble in the external
aqueous  phase.  The  organic  solvent  diffuses  immediately  to  the  external  aqueous  phase.
Therefore, neither extraction nor separation of the solvent is required for the precipitation of
the polymer.  After  the preparation of  nanoparticle,  the solvent  is  eliminated and the free
flowing nanoparticles are obtained under reduced pressure. This method is used for the drugs
that are slightly soluble in water.
Salting out:
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This  method  involves  incorporation  of  a  saturated  aqueous  solution  of  polyvinyl
alcohol (PVA) into acetone solution of the polymer under magnetic stirring to form O/W type
emulsion. The process differs from nanoprecipitation method in which the polymeric solution
is  completely  miscible  with  the  external  aqueous  medium.  But  in  this  technique,  the
miscibility of both the phases is prevented by the saturation of external aqueous phase with
PVA.
EVALUATION OF NANOPARTICLES:
The prepared nanoparticles are evaluated for various parameters like;
1. Yield
2. Drug loading
3. Entrapment efficiency
4. Size and morphology
5. In vitro drug release studies
6. Stability testing
Yield:
Percentage yield plays a crucial role in determining whether the preparation procedure
chosen for incorporating the compound in the polymeric particles is efficient. The percentage
yield is expressed as,
Yield (%) = 
initial amount of rawmaterials
amount of nanoparticles  X 100
The initial amount of raw material represents the amount of active compound and
polymer.  Certain  amount  of  stabilizing  agent  or  surfactant  is  being  adsorbed  during  the
preparation. Therefore a correction factor should be introduced.
Yield (%) = 
initial amount of rawmaterials
amount of nanoparticle X (1fraction of residual stabilizingagent ) X100
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. Page 8
INTRODUCTION
Drug loading:
 The drug loaded or drug content is expressed as;
Drug loading = 
amount of drug∈nanoparticles
amount of nanoparticles  X 100
Entrapment efficiency:
Drug  entrapment  efficiency  is  the  initial  amount  of  drug  that  is  incorporated  or
adsorbed onto the particles. It is defined as,
E.E (%) = 
drug loaded
of initial content X (1 fractionof residual stabilizing agents)  X 100
Since the size of the nanoparticles is small, the determination of the drug loading is
done after the separation of the free drug from bound drug. 
Size and morphology:
Scanning electron microscopy (SEM), transmission electron microscopy (TEM) and
photon  correlation  spectroscopy  (PCS)  are  the  most  commonly  used  instruments  for
determining the particle size of nanoparticles. 
Scanning  electron  microscopy  is  used  for  the  field  of  nanocarriers.  It  has  high
resolution and easy sample preparation. But the sample should withstand high vacuum during
analysis. To visualize the particles,  they have to be conductive.  Therefore,  coating of the
surface of the sample with gold is required. The thickness of the coating is 20nm. Depending
on the amount of the additives, the particles are partially or completely hidden in a matrix of
additives. Therefore removal of the stabilizing agents added during the preparation of the
particles is essential.
Invitro release studies:
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Due to the very small size of the particles, the release rate observed in vivo can differ
greatly from the release obtained in a buffer solution. Depending on the type, drug release
from nanoparticles takes place through the following processes;
• The solvent may penetrate the nanoparticles and dissolve the drug which then
diffuses out into the release medium.
• The drug may release out of the carrier in order to allow complete release from
the carriers.
In- vitro release kinetics of the drug entrapped in nanoparticles is evaluated
by;
I. Dialysis
II. In situ method
III. Sample separation techniques
IV. Ultra filtration at low pressure.
APPLICATIONS OF NANOPARTICLES:
 Materials: nanoparticles, carbon nanotubes, paints, biopolymer, coating.
 Ceramic  based  nanoparticles  for  entrapping  therapeutic  agent  for
photodynamic therapy.  In  this method photosensitive drug/dye is  entrapped
with ceramic carrier. These ceramic nanoparticles are widely used for skin and
therapeutic purpose.
 Nanomedicines: medical devices, nanodrug, tissue engineering etc.
 The thermo sensitive nanoparticles are used for selective release of the content
after specific localization.
INTRODUCTION TO DIABETES MELLITUS:
DIABETES MELLITUS: 7
Diabetes  has  emerged  as  a  major  health  problem  in  India.  The  prevalence  of
diagnosed diabetes has risen dramatically over the past several decades. 
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Diabetes mellitus is a group of metabolic diseases in which a person has high blood
sugar because the pancreas does not produce enough insulin or because cells do not respond
to the insulin that is produced. 
CLASSIFICATION OF DIABETES MELLITUS: 8
Diabetes mellitus is classified into four categories: type 1, type 2, gestational diabetes
and other specific types. The term "diabetes", usually refers to diabetes mellitus. The rare
disease diabetes insipidus has similar symptoms to diabetes mellitus, but without disturbances
in the sugar metabolism (insipidus means "without taste" in Latin) and does not involve the
same disease mechanisms.
Type 1 diabetes mellitus: 9
 It results from the body's failure to produce insulin and requires the person to inject
insulin  or  wear  an  insulin  pump.  This  form was  referred  as  "insulin-dependent  diabetes
mellitus" (IDDM) or "juvenile diabetes". Type 1 diabetes mellitus is characterized by loss of
the insulin-producing beta cells of the islets of Langerhans in the pancreas, leading to insulin
deficiency. There is no known preventive measure against type 1 diabetes. Sensitivity and
responsiveness to insulin are usually normal, especially in the early stages. Type 1 diabetes
can  affect  children  or  adults,  but  was  traditionally  termed  "juvenile  diabetes"  because  a
majority of these diabetes cases were in children.
 Type 1  diabetes  are  accompanied  by  irregular  and  unpredictable  hyperglycemia,
frequently with ketosis, and sometimes serious hypoglycemia including an impaired counter
regulatory response to hypoglycemia, occult infection, gastro paresis (which leads to erratic
absorption of dietary carbohydrates) and endocrinopathies (e.g., Addison's disease).  
Type 2 diabetes mellitus:
Type  2  diabetes  is  the  most  common  type.  It  results  from  insulin  resistance,  a
condition in which cells fail to use insulin properly, sometimes combined with an absolute
insulin  deficiency.  This  form was  referred  to  as  non  insulin-dependent  diabetes  mellitus
(NIDDM) or "adult-onset diabetes". In the early stage of type 2, the predominant abnormality
is reduced insulin sensitivity. At this stage, hyperglycemia can be reversed by a variety of
measures and medications that improve insulin sensitivity or reduce glucose production by
the liver.
Gestational diabetes:
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Gestational  diabetes  (GDM) occurs  when  pregnant  women  without  a  previous
diagnosis  of  diabetes  develop  a  high  blood  glucose  level.  It  resembles  type 2  diabetes,
involving  a  combination  of  relatively inadequate  insulin  secretion  and  responsiveness.  It
occurs  in  about  2–5%  of  all  pregnancies  and  may  improve  or  disappear  after  delivery.
Gestational diabetes is fully treatable, but requires careful medical supervision throughout the
pregnancy. Untreated gestational  diabetes can damage the health of the foetus or  mother.
Risks to the baby include macrosomia (high birth weight),  congenital cardiac and central
nervous system anomalies and skeletal muscle malformations. Hyperbilirubinemia may result
from red blood cell destruction. In severe cases, perinatal death may occur most commonly as
a result of poor placental perfusion due to vascular impairment. A caesarean section may be
performed if  there is  marked fetal  distress  or  an increased risk of  injury associated with
macrosomia such as shoulder dystocia. 
Other types:
• Prediabetes is a condition that occurs when a person's blood glucose levels are
higher than normal but not high enough for a diagnosis of type 2 DM. 
•  Latent autoimmune diabetes of adults (LADA) is a condition in which type 1
DM develop in adults. They are initially misdiagnosed as having type 2 DM,
based on age rather than etilogy. 
• Some  cases  of  diabetes  are  caused  by  the  body's  tissue  receptors  not
responding to insulin  (even when insulin levels are normal,  which is  what
separates it from type 2 diabetes).
•  Genetic mutations (autosomal or mitochondrial) can lead to defects in beta
cell  function.  Abnormal  insulin  action  may  also  have  been  genetically
determined in some cases.
•  Any  disease  that  causes  extensive  damage  to  the  pancreas may  lead  to
diabetes. Diseases associated with excessive secretion of insulin- antagonistic
hormones can cause diabetes. 
Table 3: COMPARISON OF TYPE 1 AND 2 DIABETES:
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Figure 1: SIGNS AND SYMPTOMS:
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Feature Type 1 diabetes Type 2 diabetes
Onset Sudden Gradual
Age at onset Mostly in children Mostly in adults
Body habitus Thin or normal Often obese 
ketoacidosis Common Rare
Auto antibodies Usually present Absent
Endogenous insulin Low or absent
Normal,
decreased
or increased
Concordance  in
identical twins 
50% 90%
INTRODUCTION
The symptoms of untreated diabetes are; 
• Loss of weight,
•  Polyuria (frequent urination), 
• Polydipsia (increased thirst) and 
• Polyphagia (increased hunger). 
 Symptoms may develop rapid in type 1 diabetes, while they usually develop much
more slowly or absent in type 2 diabetes.
Prolonged high blood glucose can cause glucose absorption in the lens of the eye,  which
leads to changes in its shape, resulting in vision changes. Skin rashes occur in diabetes which
is known as diabetic dermadromes.
PATHOPHYSIOLOGY:
Insulin is the principal hormone that regulates uptake of glucose from the blood into
most cells. Therefore, deficiency of insulin or the insensitivity of its receptors plays a major
role in all forms of diabetes mellitus.
Insulin  is  released  into  the  blood  by  beta  cells  (β-cells),  found  in  the  islets  of
Langerhans in the pancreas that raises levels of blood glucose, typically after eating. Insulin
is used by about two-third of the body's cells to absorb glucose from the blood for conversion
to other needed molecules or for storage.
Insulin controls the signal for conversion for internal storage in liver and muscle cells.
Lowered glucose levels result both in the reverse conversion of glycogen to glucose when
glucose  levels  fall  and in  the reduced release of  insulin from the β-cells.  This  is  mainly
controlled by the hormone glycagon. Glucose produced from internal  liver cell stores (as
glycogen)  re-enters  the  bloodstream.  Muscle  cells  lack  the  necessary export  mechanism.
Normally, liver cells do this when the level of insulin is low.
When  the  glucose  concentration  in  the  blood  is  raised  beyond  its  renal
threshold, reabsorption of glucose in the proximal renal tubuli is incomplete and part of the
glucose remains in the urine (glysosuria). This increases the osmotic pressure of the urine and
inhibits  reabsorption  of  water  by the  kidney which  results  in  increased  urine  production
(polyuria) and increased fluid loss.  Lost  blood volume will  be replaced osmotically from
water held in body cells and other body compartments, causing dehydration and increased
thirst.
TREATMENT: 10
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All forms of diabetes are treatable since insulin became available in 1921, and type 2
diabetes may be controlled with medications. Insulin and some oral medications can cause
hypoglycaemia (low blood sugars), which are dangerous if severe. Both types 1 and 2 are
chronic conditions that cannot be cured. Pancreas transplants have been tried with limited
success in type 1 diabetes mellitus. Gastric bypass surgery has been successful in many with
morbid  obesity  and  type 2  diabetes  mellitus.  Gestational  diabetes  usually  resolves  after
delivery.
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Pedro Tartaj11 et al., (2003) described the synthetic routes for the preparation of magnetic
nanoparticles  useful  for  biomedical  applications  and  possible  applications  of  magnetic
nanoparticles  with special  emphasis  on showing the  benefits  of  using nanoparticles.  The
importance of having well-defined synthetic routes to produce materials not only with similar
physical features but also with similar crystallochemical.
Mansoor Amiji12 et  al., (2005) developed  thiolated  gelatin  nanoparticles  to  enhance  the
intracellular delivery potential of plasmid DNA using non viral vectors. Thiolated gelatin was
synthesized by covalent modification of the primary amino groups of Type B gelatin using 2-
iminothiolane (Traut’s reagent). Cytotoxicity evaluations carried out by the formazan (MTS)
assay showed that the thiolated gelatin prepared with 20 mg and 40 mg of 2-iminothiolane
(SHGel-20 and SHGel-40) per gram of gelatin had comparable cell viability profile to that of
the unmodified gelatin. The presence of GSH was found to enhance the release by about 40%
in case of thiolated gelatin and about 20% in gelatin nanoparticles under similar conditions of
temperature and GSH concentrations. Qualitative results showed highly efficient expression
of  GFP that  remained  stable  for  up  to  96  h.  The  results  showed  that  thiolated  gelatin
nanoparticles would serve as a biocompatible intracellular delivery system that can release
the payload in a highly reducing environment.
Kunihiko Koshiba13 et al., (2006) demonstrated plasma adiponectin levels increase after the
administration of glimepiride. These unique effects would also be expected to improve other
adipocytokines and have anti- atherosclerotic action in patients with metabolic syndrome.
Thirty-four  patients  with  type  2  diabetes  mellitus  who were  administrated  glibenclamide
were randomly divided into two groups. The levels of plasma adiponectin, high sensitive-
CRP,  TNF-,  interleukin-6,  homeostasis  model  assessment-insulin  resistance  (HOMA-IR),
brachial-ankle pulse wave velocity (baPWV) and augmentation index (AI) were measured.
HOMA-IR in the GP group was significantly decreased compared to the GB group. Plasma
adiponectin levels were significantly increased in the GP group but not in the other groups.
Glimepiride appears to improve insulin resistance andatherosclerotic disorders. 
Catarina Pinto Reis14 et al., (2006) evaluated polymeric nanoparticles have been extensively
studied as particulate carriers in the pharmaceutical and medical fields, because they show
promise as a drug delivery system as a result of their controlled sustain release properties,
sub-cellular  size  and  biocompatibility  with  tissue  and  cells.  Several  methods  to  prepare
nanoparticles  have  been  developed  during  the  last  two  decades,  classified  according  to
whether  the  particle  formulation  involves  a  polymerisation  reaction  or  arises  from  a
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macromolecule  or  performed  polymer  so  as  to  facilitate  selection  of  an  appropriate
nanoencapsulation method according to a particular application.
H. O. Ammar15 et al., (2007) improved the solubility and dissolution of glimepiride through
complexation  with  dimethyl-β-cyclodextrin  (DM-β-CD).  An  inclusion  complex  of
glimepiride in DM- β-CD was prepared in a molar ratio of 1: 2 by the kneading method. The
drug-CD complex was characterized by scanning electron microscopy,  thermogravimetric
analysis and X-ray diffractometry.  Ternary systems of the drug, cyclodextrin and a water
soluble polymer (HPMC, PVP, PEG4000 or PEG6000) were also prepared. The solubility of
the  drug  increased  with  the  addition  of  cyclodextrin.  Dissolution  of  the  drug  from  the
prepared  ternary systems  was  highly dependent  on  the  polymer  type  and  concentration.
Dissolution of the drug from ternary systems containing PEG4000 or PEG6000 seemed to be
generally higher than from systems containing HPMC or PVP. This should help improve the
biological performance of the drug.
Manivannan  Rangasamy16 et  al., (2008)  developed  β-Cyclodextrin  complexation  of
meloxicam to  enhance  the  solubility  features  of  the  drug.  The  possibility  of  developing
meloxicam tablets are allowing to get fast reproducible and complete drug disintegration by
using  β-Cyclodextrin  complexation.   The  tablets  were  prepared  by  direct  compression
technique and evaluated for thickness, uniformity of weight, content uniformity, hardness,
friability,  disintegration  and  in-vitro  dissolution  time.  Stability  study  for  the  selected
formulations was conducted for a period of one month at 25˚C, 40˚C and 60˚C respectively
and the formulations exhibited no alteration in the physical  appearance or content of the
tablet.  The  complex prepared by direct  compression method was found to  be yield  very
reliable and best results over that of the wet granulation method.
V.  G.  Kuchake17 et  al.,  (2009)  studied  the  effect  of  metformin  when  it  is  given  in
combination with either glimepiride or glibenclamide on glycaemic control in patient with
type 2 Diabetes Mellitus. Patients were randomly assigned for treatment based on metformin-
glibenclamide 1000/10 mg tablets  or  metformin-glimepiride1000/2mg for  12  weeks.  The
comparisons were conducted between these two groups for HbA 1C, FPG, PPG and lipid
profile. Significant reductions in HbA1c were found in both groups but the patients treated
with metformin-glimepiride resulted in significantly greater reductions in HbA 1C (-1.4%)
than  metformin-glibenclamide  (-1.2%).  Metformin-glimepiride  tablets  resulted  in
significantly  greater  reductions  in  HbA 1C  and  fasting  plasma  glucose  compared  with
metformin plus glibenclamide in patients with type 2 diabetes mellitus.
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S.  Tamizhrasi18 et  al., (2009) prepared and evaluated polymethacrylic  acid nanoparticles
containing lamivudine in different drug to polymer ratio by nanoprecipitation method. SEM
indicated  that  nanoparticles  have  a  discrete  spherical  structure  without  aggregation.  The
particle size of the nanoparticles was gradually increased with increase in the proportion of
polymethacrylic  acid  polymer.  The  drug  content  of  the  nanoparticles  was  increasing  on
increasing  polymer  concentration  up  to  a  particular  concentration.  The  in-vitro  release
behaviour  from  all  the  drug  loaded  batches  was  found  to  be  zero  order  and  provided
sustained release over a period of 24 h. The developed formulation overcome and alleviates
the  drawbacks  and  limitations  of  lamivudine  sustained  release  formulations  and  could
possibility be advantageous in terms of increased bioavailability of lamivudine.
Vipul P. Patel19 et al., (2009) prepared the solid inclusion complexes of glipizide and β-CD
at a molar ratio of 1:1 and 1:2 by mixing, kneading, and co-precipitation methods both on
small and large scales. The effect of parameters such as kneading time and temperature on
complexation was also studied. In vitro release studies were carried out in phosphate buffer
(pH 7.4). All the methods of preparation of complexes were found to be useful in increasing
the  solubility  of  glipizide  except  mixing  method  where  the  rise  in  solubility  was  not
significant. Both kneading and co-precipitation methods in 1:2 molar ratios were found to be
equally  effective  in  improving  the  solubility  of  glipizide.  The  formation  of  inclusion
complexes was evident in these formulations as shown by IR and XRD studies. But when
carried out on a large scale, co-precipitation method was found to be more tedious and time-
consuming than kneading method. Moreover percent recovery of complexes in the kneading
method was found to be 98.76% as compared to 92.05% in case of co- precipitation method.
Inclusion complexes  prepared  by kneading method in  1:2  molar  ratios  were  suitable for
improving the solubility of glipizide. The same formulation was prepared at large scale and
optimum formulation conditions were established.
N.Arunkumar20 et al., (2009) improved the solubility and dissolution characteristics of a
poorly soluble drug (atorvastatin calcium) using nanosuspension technology. Nanoparticles
were characterized in terms of size and morphological characteristics. Saturation solubility
and  dissolution  characteristics  were  investigated  and  compared  to  the  commercial  drug.
Crystallinity  of  the  drug  was  also  evaluated  by performing  thermal  gravimetric  analysis
(TGA), differential scanning Calorimetry (DSC) and powder X-ray diffraction (PXRD). It
has  been  shown  that  the  crystalline  state  of  the  drug  is  reduced  following  particle  size
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reduction and the dissolution rates of  amorphous atorvastatin calcium nanoparticles were
highly  increased  in  comparison  with  commercial  drug  by  the  enhancement  of  intrinsic
dissolution rate and the reduction of particle size, resulting in an increased specific surface
area.
L. Zhang21 et al., (2010) developed nanoparticle systems for antimicrobial  drug delivery.
Even  though  the  therapeutic  efficacy of  the  drugs  has  been  well  established,  inefficient
delivery could  result  in  inadequate  therapeutic  index  and local  and  systemic side  effects
including  cutaneous  irritation,  peeling,  scaling  and  gut  flora  reduction.  Nanostructured
biomaterials,  nanoparticles  in  particular,  have  unique physicochemical  properties  such  as
ultra  small  and  controllable  size,  large  surface  area  to  mass  ratio,  high  reactivity,  and
functionalizable structure. These properties can be applied to facilitate the administration of
antimicrobial drugs, thereby overcoming some of the limitations in traditional antimicrobial
therapeutics. In recent years, encapsulation of antimicrobial drugs in nanoparticle systems
has  emerged  as  an  innovative  and  promising  alternative  that  enhances  therapeutic
effectiveness and minimizes undesirable side effects of the drugs.
Camelia Nicolescu22 et al., (2010) evaluated the possibilities to improve Repaglinide - an
oral antidiabetic drug -solubility in water, based on inclusion complexes formation with β-
cyclodextrin (β-CD), hydroxypropyl β-cyclodextrin (HP-β-CD) and randomly methylated β-
cyclodextrin (RAMEB), respectively,  and also to estimate their composition and apparent
stability constants. We have noticed that the phase solubility diagram for the repaglinide –
HP-β-CD inclusion complex is a type, while those of repaglinide - β-CD and RAMEB are B
type. The phase-solubility diagrams indicate an enhancement of the repaglinide solubility in
the presence of β-CD, as well as its derivatives, HP-β-CD and RAMEB in different extents,
related to the type of cyclodextrin.  
Rezaei  Mokarram23 et  al., (2010)  prepared  indomethacin  nano-solid  suspension  in  a
polymeric matrix by controlled precipitation method to increase the solubility and rate of the
dissolution  of  poorly  soluble  model  drug.  It  is  characterized  by  differential  scanning
calorimetry  (DSC),  X-ray  diffraction  (XRD),  Fourier  Transform  Infrared  Spectroscopy
(FTIR) and evaluated for in vitro solubility and dissolution rate.  Absence of thermal and
diffractional peaks in DSC and XRD studies indicated that indomethacin interacts with PVP
in solid phase. It was found that particle size distribution depend to the polymer MW and
drug: polymer ratios.  Spectroscopy methods and Transmission Electron Microscopy (TEM)
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images showed that indomethacin dispersed as amorphous nanosize particles in freeze dried
powder. 
Mitra Jelvehgari24 et al., (2010) formulated and evaluated effect of the microencapsulation
of theophylline loaded nanoparticles on the reduction of burst release. Nanoparticles were
prepared  by  using  water-in-oil-in-water  (W1/O/W2  double-emulsion  solvent
diffusion/evaporation  method),  taking  different  ratios  of  drug/polymer.  Solvent  systems
consist of ethyl acetate and dichloromethane for microspheres and nanospheres, respectively.
In the current  study formulations were characterized by loading efficiency, yield,  particle
size, zeta potential, X-ray diffraction (XRD) and differential scanning calorimetry (DSC).
The burst was significantly lower with composite microparticles and may be explained by
lower diffusion of the drug from double polymeric wall formed by the nanoparticles matrix
followed by another diffusion step through the microparticle polymeric wall.   
Partha Saha25 et al., (2010) performed ampicillin trihydrate-loaded chitosan nanoparticles
by modified ionic gelation method and evaluated their antimicrobial activity. Parameters such
as the zeta potential,  polydispersity,  particle size,  entrapment efficiency and in vitro drug
release of the nanoparticles were assessed for optimization. Scanning electron microscopy
revealed  that  the  nanoparticles  were  in  the  nano  size  range  but  irregular  in  shape.
Concentrations of 0.35 %w/v of chitosan and 0.40 %w/v sodium tripolyphosphate (TPP) and
a sonication time of 20 min constituted the optimum conditions for the preparation of the
nanoparticles.  The  nanoparticles  demonstrated  superior  antimicrobial  activity  to  plain
nanoparticles  and  the  reference,  due  probably  to  the  synergistic  effect  of  chitosan  and
ampicillin trihydrate. 
S. Debnath26 et al., (2010) prepared cytarabine loaded nanoparticles by ionotropic gelation.
This was characterized by SEM and was found to be in the range of 200nm. The mechanism
by which the drug is being released is non- Fickian (anomalous) solute diffusion mechanism.
It is evident from the result that initial burst release was retarded or delayed due to absorption
of coating material. The in vivo bio distribution study results showed that the nanoparticles
were having better distribution of drug compared to free drug in different organs like spleen,
lungs, kidney etc.
C.  Rubina  Reichal27 et  al., (2011)  developed  floating  matrix  tablets  of  glimepiride  to
prolong  the  gastric  residence  time  and  thereby  increase  drug  bioavailability.  Diabetes
condition influences the gastric emptying time which affect the absorption of the drug. The
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tablets  were  prepared  by  direct  compression  technique,  using  various  grades  of  rate
controlling  polymers,  Carbopol  934P either  alone  or  in  combination  and  other  standard
excipients.  Tablets  were  evaluated  for  physical  characteristics  viz.  hardness,  % friability,
floating  capacity  and  content  of  dosage  form.  Floating  matrix  tablets  based  on  the
combination of polymers exhibited desired floating and prolonged drug release for 8h.
Narasimha Reddy28 et  al.,  (2011) investigated the release of  Glimepiride and Parecoxib
from the dosage form at a particular site and controlling the release of drug from the dosage
form and achieving controlled plasma level of the drug as well as improving bioavailability.
The tablets were prepared to achieve controlled plasma level of the drug which is especially
in  diabetes  mellitus  patients  with  pain  therapy.  The  tablets  were  prepared  by  direct
compression technique. Both the drugs were found compatible with the excipient used. All
the formulations were found to have good pre compression and post compression parameters.
The optimized formulation was subjected to accelerated stability studies.
Neha Chowdhary29 et al., (2011) developed to improve the solubility and dissolution rate of
poorly water soluble glimepiride by complexation with HP-β-cyclodextrin and impart a fast
release in a single formulation. The complexes of glimepiride with HP-β-cyclodextrin were
physical mixing, co-grinding and kneading methods and were characterized and evaluated to
study  the  effect  on  complexation  in  dissolution  and  solubility  profiles.  Remarkable
improvement was observed in the invitro drug release profile in 0.1N HCl and phosphate
buffer pH 6.8 with all complexes. The characterization studies confirmed that the inclusion of
glimepiride  with  the  non-polar  cavity  of  HP-β-CD.  The  glimepiride:  HP-β-CD (1:3  M)
complex  prepared  by kneading  method  exhibited  higher  dissolution  rate  and  dissolution
efficiency  value  in  pH  6.8  phosphate  buffer  than  pure  drug  and  physical  mixture.  The
orodispersible tablets were formulated using the kneaded complex with suitable excipients
showed 100% release within 5 mins. Stability studies were carried out as per ICH guidelines
indicated that there was no significant change found in physical appearance, degradation time
and wetting time of the tablets.  
    
Veerendra  S.  Rajpurohit30 et  al., (2011)  prepared  solid  dispersions  of  glimepiride  by
modified solvent fusion method using PEG 6000 and PVP K25 (as carrier). Invitro release
was  carried  out  using  USP II  dissolution  apparatus.  Multilinear  regression  analysis  was
applied to develop mathematical model to estimate cumulative drug release. Improvement in
dissolution  behaviour  of  solid  dispersion  batches  was  observed  due  to  conversion  of
crystalline form of drug to amorphous form as confirmed by DSC, FTIR studies and X-RD
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studies. SEM photographs showed porous nature of particle surface. Uniformity of content of
different batches was found to be in range as specified by IP. Solid dispersion prepared via
modified fusion solvent method was proved to be beneficial in enhancement of dissolution
rate of poorly-water soluble drug using hydrophilic carriers. Retrospectively, this model can
further be utilized to design solid dispersions for desired release characteristics.
Shahrooz  Saremi31 et  al., (2011)  prepared  and  evaluated  mucoadhesive  core-shell
nanoparticles  based  on  copolymerization  of  thiolated  chitosan  coated  on  poly  methyl
methacrylate cores  as a carrier for oral  delivery of docetaxel.  It  is prepared by a radical
emulsion  polymerization  method  using  cerium  ammonium  nitrate  as  an  initiator.
Nanoparticles were spherical with mean diameter below 200 nm, polydispersity of below
0.15, and positive zeta potential values. In vitro release studies showed a sustained release
characteristic for 10 days after a burst release at the beginning. Ex vivo studies showed a
significant increase in the transportation of docetaxel from intestinal membrane of rat when
formulated as nanoparticles. It can be concluded that by combining the advantages of both
thiolated polymers  and colloidal  particles,  these nanoparticles can be proposed as a drug
carrier system for mucosal delivery of hydrophobic drugs. 
Durga Prasad Pattanayak32 et al., (2011) designed bilayer tablet formulation consisting of
two  drug  containing  layers  which  comprises  Metformin  sustained  release  layer  and  an
immediate release layer of Glimepiride was optimised separately and constituted in bilayer
tablet, a common analytical method for quantitative combined drug estimation was employed
and evaluated.  Two different  matrix  formulations  were developed,  one matrix  layer  with
hydrophilic  swellable  polymer  and  another  with  hydrophobic  polymer  as  carriers  for
sustained drug delivery from matrices and were evaluated. Hydroxypropyl methyl cellulose
and Polyethylene oxide was used as polymers in order to get the sustained release profile
over a period of 24 h. Stability of the drug release profiles at 6 months in 400 C and 75%RH
suggesting that HPMC based sustained release formulation was stable than the Polyethylene
oxide sustained release formulation due to its stable and better targeting profile in terms of
drug  release.  This  formulation  also  exhibited  the  best  fitted  formulation  into  zero  order
kinetics and non-Fickian transport of the drug from the tablets was confirmed. Bilayer tablet
prepared  from  optimised  formula  was  found  to  be  best  suited  method  for  fixed  dose
combination of sustained release Metformin HCl and immediate release Glimepiride.
Adel M. Aly33 et  al., (2011) prepared Glimepiride rapidly disintegrating tablets by direct
compression and evaluated Pharmaburst as a newly introduced diluent for this type of tablets,
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either alone or in combination with other well known tablet excipients. Pharmaburst alone is
sufficient to produce rapidly (orally) disintegrating tablets of Glimepiride with good physical
characteristics, better compatibility and shorter in-vivo and in-vitro disintegration time. The
prepared Glimepiride RDT was found to have faster onset of action than the conventional
Glimepiride tablets. Glimepiride RDT containing Pharmaburst alone were found to be stable
when subjected to accelerated stability conditions (40 °C / 75 % relative humidity) for at
least 3 months. 
Anilkumar J. Shinde34 et al.,  (2011) formulated nanoparticles for simvastatin drug. Since
simvastatin undergoes extensive first pass extraction in the liver, the availability of the drug
to the general circulation is low (< 5%). Nanoparticles were prepared by precipitation-solvent
deposition method using 3² full  factorial  designs.  The prepared formulations were further
evaluated for drug content, in vitro drug release pattern, and short term stability and drug
excipient  interactions.  Drug:  polymer  ratio  and concentration of  stabilizer  were found to
influence  the  particle  size  and  entrapment  efficiency  of  simvastatin  loaded  PLGA
nanoparticles.  The  release  was  found  to  follow  first  order  release  kinetics  with  fickian
diffusion mechanism for all batches. These results indicate that simvastatin loaded PLGA
nanoparticles could be effective in sustaining drug release for a prolonged period.
Subhranshu  Panda35 et  al., (2011)  prepared  solid  dispersions  by  solvent  evaporation
technique to enhance solubility. Different ratios of PEG 6000 to Glimepiride were taken for
solid dispersion. The Films of Glimepiride solid dispersion equivalent to 2mg Glimepiride ,
were developed by solvent casting method using different Polymers, HPMC K4M, Sodium
CMC, carbopol 971P and polyox. The prepared mucoadhesive buccal patches were evaluated
for Swelling index, Residence time, Folding endurance, Tensile strength and Mucoadhesive
strength. In vitro release was carried out in simulated saliva solution using modified USP
type  II  apparatus  at  50  rpm.  Ex  vivo  release  studies  were  performed with  few selected
batches and its results along with evaluation parameter were taken in to account to select
optimized batch. The release of Glimepiride from developed formulations was found to be
fickian diffusion controlled. A Short- term accelerated stability study was carried out for one
month and the formulation found stable for that period of time.
Chandra Sekhar Y36 at  el., (2011)  prepared  glimepiride  sustained  release  matrix  tablet
system by using natural polymers carrgeenan and xanthan gum. The sustained release matrix
tablets of glimepiride were prepared by wet granulation method varying the concentrations of
polymers. The formulated granules were evaluated for angle of repose, bulk density, tapped
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density,  Carr’s  index  and  hausner’s  ratio.  The  formulated  tablets  were  evaluated  for
uniformity weight,  hardness,  friability,  and  drug content,  invitro  swelling studies,  invitro
dissolution study and kinetic data analysis. The obtained results were clearly indicating that
the formulated tablets results are within the range. The release of drug was anomalous non-
Fickian transport of diffusion from zero order release from the formulation was observed.
Khushbu Shenghani37 et al., (2012) developed Bi-layer tablets containing two layers, one
the immediate release and one containing the extended release layer. Extended layer were
prepared  by  wet  granulation  method  using  different  viscosity  grade  of  Hydroxypropyl
methylcellulose (HPMC K100M and HPMC K200M) as polymers and immediate release
layer were prepared by wet granulation method using superdisintegrant such as sodium starch
glycolate and crosscarmellose sodium. Binder used was polyvinyl pyrollidone (PVP K-30).
The tablets  were  then  evaluated  for  the  various  physicochemical  parameters  and  for  the
dissolution profile and then the prepared batches were compared with the Reference product.
The present study concluded that Bilayer tablets of Metformin Hydrochloride as an extended
release layer and Glimepiride as an alternative to the immediate release conventional dosage
form. 
Mohammed S. Khan38 et al., (2012) developed and evaluated mucoadhesive nanoparticles
of  chitosan  using  Tramadol  HCl.  Spray  drying  method  was  employed  for  producing
nanoparticles  using  different  drug  to  polymer  ratio.  Nanoparticles  were  evaluated  for
variables like yield, drug loading, entrapment efficiency, swelling, in-vitro mucoadhesion,
particle  size,  polydispersity  index  &  zeta  potential,  scanning  electron  microscopy,
transmission electron microscopy, X-ray diffraction study and drug polymer compatibility by
Differential scanning calorimetry & Fourier Transform Infrared Radiation studies. From the
above studies it is considered that Tramadol HCl loaded chitosan nanoparticles is a promising
delivery through nasal route for relief of pain.  
Lakshmi  Sirisha  Kotikalapudi39 et  al.,  (2012)  prepared  solid  lipid  nanoparticles  of
Domperidone.  DOM  loaded  SLN  were  prepared  by  hot  homogenization  followed  by
ultrasonication technique. DOM- SLN were characterized for  particle  size,  polydispersity
index (PDI), zeta potential and entrapment efficiency and invitro drug release behaviour were
investigated. P-XRD and DSC analysis were performed to characterize the state of drug and
lipid modification. Shape and surface morphology were determined by transmission electron
microscopy (TEM). SLN formulations were subjected to stability study over a period of 30
days. Invitro release studies demonstrated that the SLN formulation possessed a controlled
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release over a period of 48 hrs. Fairly spherical shaped, stable and controlled release DOM-
SLN could be prepared by hot homogenization followed by ultrasonication technique.
Ghanshyam Patel40 et  al.,  (2012) formulated Pharmaceutical  equivalent  bilayer  tablet  of
Anti-diabetic by using the wet granulation method. In this formula one layer provide the
loading dose by immediate release and another layer provide maintenance dose up to 10 hrs
by extended release.  The drug excipients  compatibility study was carried out  with  FTIR
study. Immediate release fraction was formulated by using cross carmellose sodium (CCS) as
a disintegrating agent and sustained release fraction was formulated by using hydroxy propyl
methyl cellulose (HPMC) as a rate  controlling polymer.  The granules were evaluated for
angle of repose, bulk density, tapped density and compressibility index showed satisfactory
results. The prepared bilayer tablets were evaluated as thickness, hardness, friability and in-
vitro  release  studies.  In-vitro  dissolution  study  was  carried  out  for  10  hrs  using  USP
dissolution apparatus type II with pH phosphate buffer as dissolution medium. Stability study
was carried out for the optimized formulation at 40°C/75% RH shows that there was no
significant change in physical and chemical parameter of the tablet.
Naik J B41 et al., (2012) formulated and optimized Repaglinide (Rg) loaded Eudragit RL-100
nanoparticles as a sustained release carrier. It is developed by High Pressure Homogenizer
Emulsification (HPHE) -Solvent Evaporation method in different  ratios. The method was
optimized  using  design  of  experiments  by  employing  a  3-factor,  3-level  Design  Expert
(version  8.0.7.1)  Statistical  Design  Software  and  was  subjected  to  various  studies  for
characterization  including  Transmission  electron  microscopy,  X-ray  diffraction,
Encapsulation efficiency, Particle Size Analysis.  These studies are favourably revealed that
the mean particle  diameter  of  optimized  formulation  was  50  nm with crystalline nature.
Moreover,  formulated  nanoparticles  were  also  subjected  to  Fourier  Transform  Infrared
Spectroscopy, Differential Scanning Calorimetry for interaction between drug and polymer.
The results were positive.  Hence, the designed system could possibly be advantageous in
terms of sustained release drug delivery system, to achieve reduced dose frequency, side
effects as well improvement in patient compliance.
Madhusudhanareddy Induri42 et al., (2012) developed and validated an analytical method
for quantitative determination and dissolution studies of Glimepiride in tablets. Glimepiride
shows absorption maxima at  225 nm and obeyed  Beer’s  law in  the range of  6.0  – 14.0
µg/mL. Percentage recovery of glimepiride for the proposed method ranged from 99.32 to
100.98%  indicating  no  interference  of  the  tablet  excipients.  It  was  concluded  that  the
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proposed  method is  simple,  easy to  apply,  economical  and  used  as  an  alternative  to  the
existing spectrophotometric and non-spectrophotometric methods for the routine analysis of
glimepiride in pharmaceutical formulations and in vitro dissolution studies.
Mohd Abdul Hadi43 et al., (2012) developed sustained release tablets of glimepiride by wet
granulation  method  based  on  combination  of  hydrophilic  (HPMC15cps,  HPC)  and
hydrophobic (Ethyl cellulose) polymers. The drug excipients mixtures were subjected to pre-
formulation  studies,  physicochemical  studies,  in-  vitro  drug  release,  kinetic  studies  and
stability studies. FTIR and DSC studies shown there was no interaction between drug and
polymers. The physicochemical properties of tablets were found within the limits. The drug
release from the optimized formulation was extended for a period of 12 hrs.  The kinetic
treatment  showed  that  the  release  of  drug  follows  first  order  models.  The  optimized
formulations were subjected to stability studies and shown there were no significant changes
in drug content, physicochemical parameters and release pattern. Results of the present study
indicated the suitability of the above mentioned polymers in the preparation of sustained
release formulation of glimepiride.
Wagh V. T.44  et al., (2012) enhanced the solubility of Glimepiride by using solid dispersion
technique. The polymers used were Poloxamer 188 and Poloxamer 407 and solid dispersions
were prepared by kneading method. The solubility study was carried out to study the effect of
polymers on solubility of Glimepiride. The prepared solid dispersions were characterized by
In-vitro solubility Study, %Drug content; Fourier transforms spectroscopy (FTIR), In vitro
drug dissolution to identify the physicochemical  interaction between drug and excipients.
The dissolution studies of solid dispersion were performed by using USP II apparatus. The
solid dispersion prepared with Poloxamer 188 showed better drug release as compared to
solid dispersion prepared with Poloxamer 407. Tablet formulations were prepared by direct
compression  technique  and  developed  tablet  formulations  were  evaluated  for  various
pharmaceutical characteristics viz. hardness, % friability, weight variation, drug content, in-
vitro dissolution profiles. Thus Results showed that the solid dispersion technique by using
poloxamer successfully used for enhancing the solubility of Glimepiride.
Neha Pachisia45 et al., (2012) prepared controlled transdermal systems of glimepiride were
prepared using natural polymer chitosan for the extended and controlled delivery of the drug.
Optimization of the system was done using in vitro drug permeation studies through rat skin.
Blood glucose  reducing hypoglycemic  activity  of  the  systems  was  studied.  The in  vitro
permeation rate across the rat skin varied with the varying drug: polymer ratio in the patch.
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The present study demonstrates that this novel matrix controlled transdermal delivery system
exhibited better control of diabetes than conventional oral route.
Hari Har Prasad.M46 et al., (2012) aimed at developing a Glimepiride immediate release
tablet formulation for the effective treatment of Type-2 Diabetes mellitus (or) Non-Insulin-
Dependent Diabetes Mellitus (or) adult-onset diabetes. To provide the patients with the most
convenient mode of administration, there was a need to develop immediate release dosage
form, particularly one that disintegrates rapidly and disperses and helps in enhancing the
Bioavailability of the drug. Glimepiride immediate release tablets were formulated by using
wet  granulation  method  and  Povidone  k  30,  starch  as  binders,  croscarmellose  sodium,
Sodium Starch Glycolate, Crosspovidone as disintegrants, Lactose monohydrate as Diluent
and Magnesium stearate as Lubricant. The tablets were evaluated for Pre compression and
Post  compression Parameters  after  conducting preformulation Studies.  All  the parameters
were within the pharmacopoeial  limits and the drug disintegration time was less and the
Invitro dissolution studies showed that the drug release was fast in Formulation containing
Sodium Starch Glycolate as Super disintegrant and Povidone k 30 as binder.
Patel  Naveen47 et  al.,  (2012) designed  sustained  release  mucoadhesive  buccal  patch
formulation of Glimepiride in order to by-pass GIT and release the drug for extended periods
of time. Glimepiride is a potent drug against Diabetes mellitus-II with a half life of 3-5 hours.
Though  Glimepiride  has  100%  oral  absorption,  due  to  high  first  pass  metabolism  its
bioavailability is less. The recommended dosage is 4 mg b.i.d leading to administration of the
drug twice a day. Buccal patches were formulated using polymers Carbopol 934 P (CP 934
P),  Ethyl  Cellulose  (EC)  and  Hydroxy  Propyl  Methyl  Cellulose  (HPMC)  in  various
proportions and combinations. Tween 80 was used as permeation enhancer and glycerine as
plasticizer. The patches were prepared by solvent casting method. The designed patches were
evaluated  for  thickness  uniformity,  folding  endurance,  weight  uniformity  and  content
uniformity and swelling behaviour. In vitro diffusion studies were conducted for 24 hours in
phosphate  buffer  (pH  6.6)  solution  using  dialysis  membrane.  Formulation  containing
maximum amount  of  swellable  and  hydrophilic  polymer  HPMC K100M and CP 934 P,
showed higher swelling index and could sustain for 24 hours. This occurred due to more
hydrophilic polymeric matrix composition which retarded the release of the drug.
Sreenivasa  Rao  K48 et  al., (2012)  prepared  and  characterized  inclusion  complexes  of
Glimepiride with β-CD and HP-β-CD. The phase solubility analysis indicated the formation
of 1:1 molar inclusion complex of Glimepiride with β-CD and HP-β-CD. Apparent stability
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constant  (KC)  was  32.95  M-1  and  42.57  M-1  for  β-CD  and  HP-β-CD  complexes
respectively.  The  inclusion  complexes  were  prepared  by  three  different  methods  viz.
Physical,  Kneading  and  Co-precipitation  method.  The  prepared  complexes  were
characterized  using  FT-IR,  and  Differential  Scanning  Colorimetry  (DSC).  The  inclusion
complex prepared with HP-β-CD by Kneading method exhibited greatest enhancement in
solubility and fastest dissolution (97.41% GMP release in 60 min) of GMP.  
P.  Srinivas49 et  al., (2012)  prepared  controlled  release  formulation  of  Moxifloxacin
hydrochloride ocular nanoparticles by solvent displacement method using Eudragit RL 100
as a polymer. Different formulations were prepared by varying the ratios of drug and polymer
and varying the ratios of organic and aqueous phase. The formulations were evaluated in
terms of particle size, FTIR, drug entrapment efficiency and in vitro drug release profile. The
anti bacterial activity against gram positive and gram negative bacteria were determined. In
vivo  studies  were  carried  out  by  Draize  test.  The  mean  particle  size  for  drug  loaded
formulations was found to be below 200 nm. The zeta potential remained in the range of
positive values for all batches +10 mV to +40mV. The formulation possesses good antibiotic
activity against Escherichia coli, Bacillus subtilus and Staphylococcus aureus microorganism
and no eye irritation on in-vivo testing.
Jaimin D patel50 et al., (2012) prepared methotrexate loaded ethyl cellulose nanoparticles
using  solvent  evaporation  method  with  PVA as  dispersion  medium.  Nanoparticles  with
varying drug: polymer ratio and dispersion medium were prepared   by using 32 factorial
designs. Prepared nanoparticles were evaluated with respect to particle size, drug entrapment
efficiency  and  in  vitro  release  study.  In-vitro  release  pattern  of  Methotrexate  from
Nanoparticles in the phosphate buffer of pH 7.4, showed a biphasic pattern with an initial
burst  effect  and prolonged release over  24hrs.  Stability studies showed that  similar  drug
content and closest in vitro release profile to initial data when the sample stored at 250C.
Shantanu Tamuly51 et  al., (2012) prepared calcium phosphate nanoparticles  with bovine
serum albumin using different stirring times and each analysed for entrapment efficiency.
The void calcium phosphate nanoparticles were injected intramuscularly into rats for testing
the  site-specific  inflammation.  The  muscle  samples  were  collected  on  the  14th  day  of
injection. The smallest particle size of about 40 µm of calcium phosphate nanoparticle–BSA
complex was obtained by stirring for 1 h. The void calcium phosphate nanoparticles did not
elicit  any site-specific  reaction  in  rats,  as  revealed  by  in  histopathological  examination.
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Hence calcium phosphate nanoparticles can be efficiently used as an adjuvant for non-live
vaccines. 
Swati  Srivastava52 et  al., (2012)  compared  the  efficacy  and  safety  of  sitagliptin  and
glimepiride in treatment of patients with type 2 diabetes mellitus inadequately controlled
with metformin alone.  In  an 18 week,  randomized  parallel  group  interventional  trial,  50
subjects  who  were  only  on  metformin  as  antidiabetic  agent,  with  inadequate  glycaemic
control, were randomized to either sitagliptin 50/100mg or glimepiride 1/2 mg per day. Dose
of drugs was adjusted after 4 weeks if glycaemic control was not reached. At 18 weeks both
groups (sitagliptin and glimepiride) produced significant (P<0.001) reduction in hbA1c (-
0.636% and -1.172% respectively), with 12% patients in sitagliptin group and 36% patients
in glimepiride group achieving target hbA1c. Reduction was also significant (P<0.001) in
both  groups  in  FPG  (-15.49mg  and  -29.84mg  respectively)  and  2hPPG  (-34.28mg  and
-44.83mg respectively).  Sitagliptin group showed net  decrease in bodyweight  by 0.102kg
whereas glimepiride group showed net increase in body weight by 0.493 kg. Incidence of
hypoglycemia  was  4%  in  sitagliptin  group  and  8%  in  glimepiride  group.  In  this  study
addition  of  sitagliptin  and  glimepiride  to  metformin  monotherapy,  produced  significant
improvement in glycaemic control. Benefits were more with glimepiride in comparison to
sitagliptin. Sitagliptin was well tolerated, with lower risk of hypoglycemia than glimepiride,
and produced weight loss as compared to weight gain with glimepiride.
Hindustan  Abdul  Ahad53 et  al., (2012)  developed  matrix  tablets  of  glimepiride  with
Hibiscus  rosa-sinensis  leaves  mucilage  and  Povidone and  to  study its  functionality  as  a
matrix forming agent for sustained release tablet formulations. Mucilage from Hibiscus rosa-
sinensis was extracted, isolated, purified and characterized. Physicochemical properties of
the  dried  powdered  mucilage  of  Hibiscus  rosa-sinensis  leaves  were  studied.  Various
formulations  of  glimepiride  Hibiscus  rosa-sinensis  leaves  mucilage  and  Povidone  were
prepared. The formulated tablets were tested for mechanical properties, friability, swelling
behaviour,  invitro  drug  release  pattern  and  the  dissolution  data  were  subjected  to
mathematical modelling and the optimized formulation were tested for accelerated stability
studies.  The  formulated  tablets  were  found  to  have  good  mechanical  properties,  good
swelling properties. The invitro dissolution data was fitted to zero order and the release of the
drug  from  the  formulation  followed  Higuchi’s  release.  The  accelerated  stability  studies
revealed that the tablets retain their characters even after stressed storage conditions. From
this  study  it  was  concluded  that  the  dried  Hibiscus  rosa-sinensis  leaves  mucilage  and
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Povidone combination can be used as effective matrix forming material for making sustained
release matrix tablets of glimepiride.
Shirse Prabhakar54 et  al., (2012) enhanced the solubility and dissolution of the drug by
preparing  its  complex  with  β-cyclodextrin  and  Hydroxypropyl  beta  cyclodextrin-β-
cyclodextrin.  In  this  present  study  attempts  has  been  made  to  prepare,  formulate  and
characterize inclusion complexes of glimepiride with β-cyclodextrin and Hydroxypropyl beta
cyclodextrin-β-CD. The inclusion complexes were prepared by three different methods viz.
Physical,  kneading  and  co-precipitation  methods.  The  inclusion  complex  containing
glimepiride: β-CD and Hydroxypropyl beta cyclodextrin-β-CD were further formulated into
fast dissolving tablets(FDT) by direct compression technique using super-disintegrants like
crosscaramelose  sodium,  crosspovidone  and  sodium  starch  Glycolate  were  used.  The
prepared complexes were characterized using DF-IR and differential scanning calorimetry
and finally the prepared fast dissolving tablets were evaluated for various pharmaceutical
characteristics viz. Hardness, %friability, weight variation, wetting time, drug content and
invitro dissolution profiles. The results of stability studies revealed to change in physical
appearance,  hardness,  drug  content  and  invitro  dissolution  profile,  thus  indicating  that
formulation was stable.     
Prabhakar Shirse55 et al., (2012) formulated and evaluated the bilayered tablets containing
immediate release layer of HP-β-Cyclodextrin inclusion complexed Glimepiride to produce
immediate therapeutic effect and sustained release layer containing Metformin Hcl by using
HPMC  as  release  retardant.  The  reason  for  Bi-  layer  tablet  formulation  is  to  separate
physically or chemically incompatible ingredients and to produce repeat action or prolonged
action tablet.  To optimize and  develop  a  robust  and  stable  formulation,  both wet  & dry
granulation processes were used for formulation.  The compressed tablets were evaluated for
physico-chemical  properties.  The stability studies  of  the products  also  comply with ICH
guidelines.  FTIR  studies  clearly  indicate  that  there  is  no  drug  polymer  interaction.  This
formulation also exhibited the best fitted formulation into zero order kinetics and non-Fickian
transport  of  the  drug  from the  tablets  was  confirmed.  The present  study concluded  that
bilayer  tablets  of  Glimepiride  &  Metformin  Hcl  shall  be  a  good  method  to  improve
bioavailability of drugs.
Kishore K56 et al., (2013) prepared solid dispersion of Glimepiride to enhance the solubility.
It is prepared by dissolving drug and polyvinyl pyrrolidine K30 in dichloromethane and the
solvent is removed by rotary evaporator  under reduced pressure.  The solubility increased
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around twenty times greater when drug and carrier is used in1:10 ratios. The Oro dispersible
tablets  were  prepared  by  using  Sodium  starch  glycollate,  cross  caramellose  sodium,
pregelatinized starch and polacrilin potassium as super disintegrants. The rapid disintegration
is obtained to polacrilin potassium (10%) and maximum drug release obtained in 10 min.
From these results  it  is concluded that solubility of glimepiride is increased by preparing
solid dispersion and rapid bioavailability is observed by preparing orodispersible tablets.  
M. Tejakrishna57 et al., (2013) developed sustained release of Glimepiride to enhance the
gastrointestinal residence time, for this purpose mucoadhesive micro beads were formulated
by  employing  Ionic  gelation  method  with  HPMC  and  Na  CMC  as  coating  polymers.
Formulated mucoadhesive micro beads were properly evaluated for size distribution, tapped
density entrapment efficiency, wall thickness, drug release studies, SEM and GI residence
time. The rate of drug release was found to be decreased by increasing the concentration of
the coat polymer. The rate of drug release was found to be less for mucoadhesive micro beads
formulated by Na CMC than compared to mucoadhesive micro beads formulated by HPMC.
The mucoadhesive micro beads prepared with HPMC and Glimepiride in 1:9 ratio shown
prolonged  drug  release  up  to  12  hours.  The  release  follows  first  order  kinetics  and
mechanism of drug release was found to be governed by diffusion mechanism.  
Ram Alpana58 et al., (2013) prepared Solid dispersions of tolbutamide with urea, sorbitol
and  mannitol  by fusion  method  with  a  view to  increase  its  water  solubility.  The  major
problem with this drug is its very low solubility in biological fluids which results in poor
bioavailability  after  oral  administration.  Therefore  Solid  dispersions  of  tolbutamide  with
urea, sorbitol and mannitol were prepared by fusion method with a view to increase its water
solubility.  The equilibrium solubility study showed that the solubility of tolbutamide was
enhanced 3.90 times in the prepared urea solid dispersion. 
Yashavantsinh Chavd59 et al., (2013) formulated and evaluated lamivudine microspheres
using a combination of eudragit  RS 100 and eudragit  RL 100 polymers.  The lamivudine
microspheres were prepared by the solvent evaporation method using different concentration
of the Eudragit polymers. The effect of polymer ratio on % drug encapsulation efficiency was
investigated using 3 full factorial designs. The parameters determined were bulk density, tape
density, angle of repose, particle size, drug content, % drug encapsulation efficiency & in
vitro  dissolution.  As  the  stirring  speed  increased,  the  particle  size  decreased  and  as  the
concentration of  eudragit  increases,  the  particle  size also  increased.  Larger  microspheres
showed greater drug loading and smaller microspheres showed a faster drug release.
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Vyjayanthimala60 et al., (2014) prepared chitosan Nanoparticles of Zidovudine for antiviral
therapy by emulsion droplet coalescence method. The concentration of the polymer Chitosan
was selected based on the results on preliminary screening. The nanoparticles prepared were
evaluated for morphology, loading efficiency and in vitro release.  The particle shape and
morphology of the prepared Zidovudine nanoparticles were determined by SEM analysis.
The amount of Zidovudine entrapment in the nanoparticles was calculated by the difference
between the total amount of drug added to the nanoparticle and the amount of non-entrapped
drug  remaining  in  the  aqueous  supernatant.  A Franz  diffusion  cell  was  used  to  monitor
Zidovudine release from the nanoparticles. The percentage cumulative drug release after 12
hours was 75.54% and 75.89% respectively. However about 15% initial burst release was
found at  1  hour  in  all  formulations.  In-vitro  antiviral  study revealed that  the formulated
nanoparticles were found to have good viral activity.
Yun  Mo61 et  al., developed  a  lectin-conjugated  isopropyl  myristate  (IPM)-incorporated
PLGA nanoparticle system (NP) for the local delivery of paclitaxel to the lungs. Wheat germ
agglutinin (WGA) was conjugated onto preformed IPM- and paclitaxel-loaded PLGA NPs by
a two-step carbodiimide method. WIT-NP with mean diameter of 331 nm and zeta potential
of _4.3 mV were prepared with yield of 66% and paclitaxel encapsulation efficiency of 61%.
Particle  size  was  expanded  by surface  conjugation  with  WGA,  while  zeta  potential  was
reduced by the addition of IPM and WGA. In vitro paclitaxel release profile was not affected
by WGA but initial drug release was enhanced by adding IPM into the formulation. 
L.X.  Tiefenauer62 et  al., developed  magnetite  nanoparticles,  coated  by  three  different
artificial polypeptides, conjugated to an antibody specific to the carcinoembryonic antigen
(CEA).  To  protect  the particles  from fast  blood elimination,  the coats  were  modified by
various sugars, polyethyleneglycol, albumin, and sialoproteins, respectively. The protective
effect was determined by using a specific in vitro test and by analyzing the biodistrlbution of
the nanoparticles in nude mice grafted with CEA-tumors. In particular, a prolongation of the
blood circulation time has  been expected,  if  a  natural  modifier  is  attached to  the coated
nanoparticles. The usefulness of nanoparticles as image contrast agents is probably limited by
their microdistribution within the tumor tissue. 
Asuman  Bozkir63 et  al., designed  to  optimize  the  formulation  of  5-fluorouracil  (5-FU)
loaded  poly  D,  L  (lactide-co-  glycolide)  (PLGA)  nanoparticles  (5FU-NP)  by  a
nanoprecipitation-solvent displacement technique. Optimized formulations have the particle
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size ranging from 160 to 250 nm. Smallest nanoparticles (161 ± 1.22 nm) were obtained
using  Resomer  PLGA 755 and  pluronic  F-68  with  10  ml  acetone  amount.  Under  these
conditions the 5-FU entrapment percentage was maximum 78.30%, suggesting 5-FU might
be entrapped and adsorbed on the nanoparticle surface. In vitro release of the formulations
with maximum drug entrapment efficiency and minimum particle size, were also investigated
by release kinetics. According to the determined coefficients, release data fit  to Higuchi’s
diffusion kinetics. The in vitro release of 5FU-NP in phosphate buffered saline (PBS, pH 7.4)
is suggested to be controlled by a combination of diffusion with slow and gradual erosion of
the particles.
C. Schwarz64 et al., prepared solid lipid nanoparticles (SLN) of a quality acceptable for i.v.
administration. Dynasan 112 and Compritol ATO 888 were used as lipid matrices for the
SLN, stabilisers were Lipoid S 75 and poloxamer 188, respectively. Changes in particle size
distribution during lyophilisation could be minimised by optimising the parameters of the
lyophilisation process, i.e. freezing velocity and redispersion method. Lyophilised drug-free
SLN could be reconstituted in a quality considered suitable for i.v. injection with regard to
the size distribution. Loading with model drugs (tetracaine, etomidate) impairs the quality of
reconstituted  SLN.  However,  the  lyophilisate  quality  is  sufficient  for  formulations  less
critical to limited particle growth.
P.K. Gupta65 et al., described the methods of evaluating targeted drug delivery systems have
been  reviewed.  It  has  been  observed  that  in  most  instances  the  parameters  used  for  the
evaluation do not necessarily provide true quantitative differences between the selectivity of
test and conventional delivery systems. It has been shown that the inadequate collection of
data  may  lead  to  misinterpretation  of  the  efficacy  of  drug  delivery  systems.  Some
mathematical relationships have been suggested and their usefulness substantiated with the
aid of data describing the disposition of adriamycin administered to rats as a solution and via
liposomes.
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Targeted drug delivery system is designed to improve the risk ratio of any drug. It
decreases  the distribution in  unwanted tissues  and makes  the drug more available in  the
required tissue.
The present study was aimed to develop glimepiride nanoparticle. Since glimepiride
has poor solubility, cyclodextrin complexes are used to enhance the solubility. It  results in
prolonged action with controlled release manner.
Glimepiride is a sulphonylurea group used for the lowering of blood glucose level
which belongs to third generation hypoglycemic drug with long duration of action. Currently
available dosage form shows some side effects like dizziness, fast heartbeat, itching, tightness
in the chest wheezing, bleeding gums, dark urine, headache, fever.
Thus the present investigation was carried out for the following objectives;
 Prolonged action
 Controlled release
 To achieve maximum bioavailability
 To reduce side effects
 To improve solubility
 To overcome therapeutic efficacy
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Plan of the work involves the following process;
• Preformulation studies which involves the observation of physical and chemical data.
The infrared spectrophotometry is used to identify the raw materials and compatibility
studies between drug and the polymer used.
• Fabrication of glimepiride cyclodextrin complexes nanoparticles is done by kneading
method.
• Fabrication of the nanoparticles in various ratios of the drug and the polymer.
Based on the result of the following parameters, the best formulation will be
selected.  The  prepared  nanoparticle  is  evaluated  by  the  following  chemical
characteristics.
• Drug content 
• Drug entrapment efficiency
• In vitro drug release studies
• Scanning electron microscope
• Zeta potential analysis
• Stability studies at different temperature
• Drug release kinetics studies
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INSTRUMENTS AND MATERIALS USED:
Table 4: Instruments used
S.N
O
                       EQUIPMENTS                     SUPPLIERS
   1 Rotary flash evaporator Equitron, Mumbai.
   2 Probe sonicator Bandelin, Germany.
   3 Single beam UV spectrophotometer Shimadzu corporation, Japan.
   4 Electronic balance Shimadzu.
   5 FTIR spectrophotometer Perkin Elmer, Germany.
   6 Double beam UV spectrophotometer Perkin Elmer, Germany.
   7 Vortex mixer Remi motors Ltd, Mumbai.
   8 Magnetic stirrer Remi motors Ltd.
   9 Stability chamber Osword, Mumbai.
  10 Ultra centrifugation Remi motors Ltd, Mumbai.
  11 pH meter Elico Pvt Ltd, Chennai.
  12 Hot air oven Biochemicals, Mumbai.
Table 5: Materials used
S.N
O
                               MATERIALS                           SUPPLIER
  1. Glimepiride Yashica pharmaceutical Pvt Ltd, 
Thane.
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  2. β- cyclodextrin Bafna pharmaceuticals, Mumbai.
  3. Poly ethylene glycol 6000 Microlabs, Hosur.
  4. Tween 80 Microlabs, Hosur.
  5. Acetone Marck, India.
  6. Potassium dihydrogen phosphate S.D.Fine chemicals Ltd, Boisar.
  7. Sodium chloride S.D.Fine chemicals Ltd, Boisar.
  8. Membrane filter Gotting Ltd, West Germany.
  9. Ethanol Marck, India.
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GLIMEPIRIDE:
1-[[p-  [2-(3-  ethyl-4-methyl-2-oxo-3-pyrroline1-  carboxamido)  ethyl]  phenyl]
sulphonyl]-3-(trans-4-methyl cyclohexyl) urea.
Chemical structure:
Molecular formula:
C24H34N4O5S
Description:
A white powder.
Melting point:
207 °C
Solubility:
Insoluble in water,  soluble in acetone, dimethyl formamide.
Pharmacology:
In Type 2 diabetes, it is considered that the lowered insulin secretion and the lowered
insulin sensitivity cause hyperglycemia. Glimepiride, a new sulfonylurea, has a blood-glucose
lowering effect as strong as those of existing sulfonylureas, but only induces mild insulin
secretion. The association and dissociation to the sulfonylurea receptor of glimepiride are
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faster.  Additionally,  it  is  confirmed by basic studies that  part  of  the glimepiride effect  is
attributable to improving insulin sensitivity. Glimepiride has already been used in more than
60  countries  in  the  world.  Glimepiride  is  expected  to  be  a  new efficient  agent  for  the
treatment of Type 2 diabetes.
Mechanism of action:
The mechanism of  action of  glimepiride  in lowering blood glucose  appears  to be
dependent  on  stimulating  the  release  of  insulin  from  functioning  pancreatic  beta  cells.
Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell
surface, reducing potassium conductance and causing depolarization of the membrane. This
increase in intracellular calcium ion concentration induces the secretion of insulin.
Pharmacodynamics:
Glimepiride is used with diet to lower blood glucose by increasing the secretion of
insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Pharmacokinetics:
Absorption:
Studies with single oral doses of glimepiride in healthy subjects and with multiple
oral doses in patients with type 2 diabetes showed peak drug concentrations (Cmax) 2 to 3
hours post-dose. When glimepiride was given with meals, the mean Cmax and AUC (area
under the curve) were decreased by 8% and 9%, respectively.
Glimepiride  does  not  accumulate  in  serum  following  multiple  dosing.  Clearance  of
glimepiride after oral  administration does not change over the 1 mg to 8 mg dose range,
indicating linear pharmacokinetics.
Distribution:
After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8
L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was
greater than 99.5%.
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Metabolism:
Glimepiride is completely metabolized by oxidative biotransformation after either an
intravenous or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative
(M1)  and  the  carboxyl  derivative  (M2).  Cytochrome  P450  2C9  is  involved  in  the
biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several
cytosolic enzymes. M2 is inactive.
Excretion:
When C-glimepiride was given orally to 3 healthy male subjects, approximately 60%
of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80-
90% of the radioactivity recovered in the urine.  The ratio of M1 to M2 in the urine was
approximately 3:2 in two subjects and 4:1 in one subject. Approximately 40% of the total
radioactivity was recovered in faeces. M1 and M2 accounted for approximately 70% (ratio of
M1 to M2 was 1:3) of the radioactivity recovered in faeces. No parent drug was recovered
from urine or faeces. After intravenous dosing in patients, no significant biliary excretion of
glimepiride or its M1 metabolite was observed.
Adverse effects:
Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances,
occasional  allergic  reactions,  and  rarely  blood  production  disorders  including
thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the
risk  of  hypoglycemia  may be  increased.  Alcohol  consumption  and  exposure  to  sunlight
should be restricted because they can worsen side effects.
Dosage:
Glimepiride tablets USP 4mg once a day.
Storage:
Stored at 20° to 25°C (68° to 77°F).
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β- CYCLODEXTRIN:
Non- proprietary names: 
BP:        betadex
USPNF: betadex
Synonyms: 
Beta-cycloamyloses,beta-dextrin,  cavamax  W7  pharma,  cyclohepta  amylase,
cycloheptaglucan, cyclomaltoheptose, kleptose.
Chemical name and CAS registry number:
β- Cyclodextrin [7585-39-9]
Empirical formula and molecular weight: 
β- Cyclodextrin C42H70O35 =1135. 
Structural formula:
Note: the structure of β- cyclodextrin (7 glucose units) is shown.
R’, R’’ = H for natural α, β, γ- cyclodextrins.
R’, R’’ = CH3 for methyl cyclodextrins.
R’, R’’ = CHOCH3 for 2- hydroxyethyl cyclodextrins.
Dept. of Pharmaceutics, K.M. College of pharmacy, Madurai. Page 42
POLYMER PROFILE
R’, R’’ = CH2CHOHCH3 for 2- hydroxypropyl cyclodextrins.
Functional category:
Solubilising agents, stabilising agents.
Applications in pharmaceutical formulations or technology:
β-  Cyclodextrin  is  the most  commonly used cyclodextrin,  although it  is  the  least
soluble. It is the least expensive cyclodextrin. It is commercially available from a number of
sources  and  it  is  able  to  form  inclusion  complexes  with  a  number  of  molecules  of
pharmaceutical interest. However, β- cyclodextrin is nephrotoxic and should not be used in
parental formulations.
In parental formulation, cyclodextrin have been used to produce stable and soluble
preparations  of  drugs  that  would  otherwise  have  been  formulated  using  a  non-  aqueous
solvent. In  eye  drop  formulation,  cyclodextrin  form water  soluble  complexes  with
lipophilic  drugs  such  as  corticosteroids.  They  have  been  shown  to  increase  the  water
solubility of the drug to enhance the drug absorption into the eye, to improve the aqueous
stability and to reduce local irritation.
Cyclodextrin have also been used in the formulation of solutions, suppositories and
cosmetics.
Description:
Cyclodextrins occur as white, practically odourless, fine crystalline powder having a
slightly sweet taste. Some cyclodextrin derivatives occur as amorphous powder.
Typical properties:
Compressibility               _ 21.0 – 44.0% for β- cyclodextrin.
Density (bulk)                 _ 0.523 g/cm3.
Density (tapped)              _ 0.754 g/cm3.
Melting point                 _ 255 – 2650C.
Moisture content              _ 13.0 – 15.0% w/w.
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Particle size distribution  _ 7.0 – 45.0
 µm.
Physical characteristics:
Characteristics                                    β- cyclodextrin
Cavity diameter (Å)                             - 6.0 - 6.5
Height of torus (Å)                               - 7.9
Diameter of periphery (Å)                    - 15.4
Approximate volume of cavity (Å)       - 262
Approximate cavity volume                  
Per mol cyclodextrin (ml)         - 157
Per gram cyclodextrin (ml)       - 0.14
Solubility:
β- Cyclodextrin is soluble in 1 in 200 parts of PEG, 1 in 50 parts of water at 20o C,
practically insoluble in acetone, ethanol (95%) and methylene chloride.
Surface tension: (at 25o C)
β- CD: 71 dynes/cm. 
Stability and storage conditions:
β- cyclodextrin and other cyclodextrins are stable in solid state if protected from high
humidity. Cyclodextrins should be stored in a tightly sealed container in a cool, dry place.
Incompatibilities:
The activity of some anti-microbial preservatives in aqueous solution can be reduced
in the presence of hydroxypropyl-β- CD.
Safety:
Cyclodextrins  are  starch  derivatives  and  are  mainly  used  in  oral  and  parentral
pharmaceutical formulation. They are used in topical and ophthalmic formulations.
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POLYEHYLENE GLYCOL 6000:
Pharmacy equivalent name: 
PEG6000
Chemical name:
 Poly (oxy- 1, 2- ethanediyl), 2- hydroxy polyethylene glycol.
Category:
 Pharmaceutical aid (ointment base, suppository base, tablet excipients).
Description: 
White free flowing powder or creamy white flasks. It is practically odourless
and tasteless.
Solubility:
Freely soluble in water, alcohol and chloroform. Insoluble in ether.  
 Structure:
                     H                       CH2                                            OH
                                O                              CH2
                                                                               n             
PEG6000  is  a  polymer  of  ethylene  oxide  and  water,  represented  by  the  formula
H(OCH2CH2)nOH, in which the average value of n lies between 158 and 204.
Congealing range:
Between 56 and 63.
Average molecular weight:
The average molecular weight is between 7000 and 9000.
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Viscocity:
Between 470 centistrokes and 900 centistrokes, at 210oF, expressed kinematics
viscosity.
Storage:
Stored in tightly closed container.
Uses:
Generally PEG6000 is used in chewable tablets and tablet formulation that require
water solubility. It is a non-reactive and can be used in pH sensitive (stable) drugs such as
aspirin and vitamins. PEG solutions can be sprayed in aqueous or hydroalcoholic solvents
into powders in twin- shell or double- cone blenders. However, they are not available in small
particle size. Also used if food and food packaging. It may also be used in cosmetics and in
ointments.
TWEEN 80:
Synonym:
Polysorbate 80,  armotan PMO 20, Tween 80.
Chemical name:
Polyoxy ethylene  20 sorbitan mono oleate.
Molecular weight:
1310.
Functional category:
Emulsifying agent,  non- ionic surfactant,  solubilising agent,  wetting,  dispersing or
suspending agent.
Description: 
Polysorbates  have  a  characteristic  odour  and  a  warm,  somewhat  bitter  taste.  The
colour of polysorbate 80 is yellow, it is an oily liquid.
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POLYMER PROFILE
Properties:
Acidty/ alkalinity: pH=6.0 – 8.0 for a 5% w/v aqueous solution.
Solubility: soluble in ethanol and water, insoluble in mineral oil and vegetable oil.
Incompatibilities:
Discolouration and or precipitation occur with various substance especially phenols,
tannins, tars and tarlike materials.  The anti-  microbial activity of paraben preservatives is
reduced in presence of polysorbates.
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CONSTRUCTION OF STANDARD CURVE OF GLIMEPIRIDE:
By UV spectroscopy method:
Glimepiride  is  estimated  spectrophotometrically  at  228nm  and  it  obeys  Beer-
Lambert’s law in the range of 1-10µg/ml.
Determination of absorbance maximum (λmax):
Glimepiride was dissolved in phosphate buffer saline pH 7.4. Solution with 10µg/ml
concentration  was  prepared  by  suitable  dilution.  The  solution  was  scanned  in  UV
spectrophotometer at 200-400 nm using phosphate buffer saline pH 7.4 as blank. Absorbance
maximum  was  determined  at  228nm.  The  drug  was  later  quantified  by  measuring  the
absorbance at 228nm in phosphate buffer saline pH 7.4.
Preparation of pH 7.4 phosphate buffer saline:66
6.8gms of potassium dihydrogen orthophosphate and 1.6gms of sodium hydroxide
were accurately weighed and transferred into 1000ml volumetric flask. The volume is made
upto 1000ml with distilled water. The pH was adjusted if necessary.
Preparation of stock solution:
Stock solution was prepared by dissolving 50mg of glimepiride in 50ml of the solvent
medium, so as to get a solution of 1000µg/ml concentration (primary stock solution). From
the primary stock solution, 1ml was taken in 100ml standard flask and it is diluted to 100ml
with the solvent medium (secondary stock solution) to get a concentration of 10µg/ml.
Preparation of standard solution:
From the secondary stock solution, aliquots  ranging from 1-10 ml was taken and
made upto 10ml with the solvent medium to get  the final  concentration ranging from 1-
10µg/ml.  Absorbance of the solution was measured at 228nm UV spectrophotometrically
against drug free phosphate buffer pH 7.4 media as blank.
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EXPERIMENTAL INVESTIGATION
Table 6: Calibration curve of glimepiride at 228nm:
Fig 2: Standard curve of glimepiride:
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S.No Concentration
(µg/ml)
  Absorbance  at
228nm
  1           1                 0.080
  2           2                 0.151
  3           3                 0.225
  4           4                 0.301
  5           5                 0.373
  6           6                 0.441
  7           7                 0.516
  8           8                 0.591
  9           9                 0.668
  10          10                 0.746
EXPERIMENTAL INVESTIGATION
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METHOD  OF  PREPARATION  OF  GLIMEPIRIDE-  CYCLODEXTRIN
COMPLEXES:
Kneading method:
The glimepiride-cyclodextrin complexes were prepared by kneading method. 10mg of
the drug,  4mg of  β-  cyclodextrin  and 20mg poly ethylene glycol,  2mg of  tween-80were
taken. The mixture was heated and 20ml of acetone was added to it. This was then sonicated
using probe sonicator set at 60W of energy output for 90 secs. This was further evaporated by
flash rotatory evaporator for 60mins.
Table 7: Various compositions of formulations:
S.No
Formulation
code
Drug
(mg)
β- CD
(mg)
PEG
(mg)
Tween
80 mg
ratio
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EXPERIMENTAL INVESTIGATION
1 CD1        4      4     20       2 1:1:5:2
2 CD2        4      8     20       2 1:2:5:2
3 CD3        4      12     20       2 1:3:5:2
4 CD4        4      16     20       2 1:4:5:2
5 CD5        4      20     20       2 1:5:5:2
6 CD6        4      24     20       2 1:6:5:2
7 CD7        4      28     20       2 1:7:5:2
8 CD8        4      32     20       2 1:8:5:2
9 CD9        4      36     20       2 1:9:5:2
10 CD10        4      40     20       2 1:10:5:2
EVALUATION OF NANOPARTICLES: 67
Drug entrapment study:
The  entrapment  efficiency  study  was  determined  by  free  drug  content  in  the
supernatant which is obtained after centrifugation at 15000rpm for 20mins at 00 using ultra
centrifuge. The absorbance was measured by UV spectrophotometer at 228nm.
IN VITRO DRUG RELEASE STUDIES: 68, 69.
By UV spectrophotometric method: 70
The  in  vitro drug  release  study  was  carried  out  using  the  diffusion  membrane
technique. The nanoparticle preparation was placed in a dialysis membrane and it is kept in a
beaker containing 100ml of diffusion medium (phosphate buffer pH 7.4). The medium was
maintained at 370 C under magnetic stirring at constant speed. 1ml of the sample was taken
from the diffusion medium at a fixed time interval. 1ml of fresh medium was replaced. This
process  was  carried  out  for  24  hours.  The  sample  was  measured  at  228nm  using  UV
spectrophotometer. The percentage of drug released at various time intervals was calculated
from calibration graph.
Morphology of nanoparticles by simple microscopy:
The  optimized  formulation  was  morphologically  characterized  by  microscopy.  A
small amount of sample was placed in a glass slide and investigated in microscopy.
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Scanning electron microscopy: 71
The  formulation  was  morphologically  characterized  using  scanning  electron
microscopy (SEM). For SEM analysis, the sample was mounted in a scotsch double adhesive
tape. The sample was analysed in hitachi scanning electron microscope operated at 15 kv and
photograph was taken.
Surface charge (zeta potential) determination: 72
Zeta  potential  is  an  important  parameter  to  evaluate  an  optimum  condition  for
stability of colloidal or dispersed systems. The prepared nanoparticles were characterized by
using  zeta  potential  analyser  (Malvern  Zeta  seizer).  Zeta  potential  creates  an  electrical
barrier. It is very important for drug stability. The effect of β- cyclodextrin complexes on the
surface of the nanoparticles was studied.
pH and physical appearance:
The pH of  the  formulation was  measured  using pH meter.  It  plays  a  role in  the
process of stability and formulation activity. The physical appearance of the formulation like
colour and suspended foreign particulate were to be examined.
Stability studies of nanoparticles:
The stability studies of nanoparticles involve observing the formulation at 450C/70%
RH which constitutes accelerated condition at 40C on refrigerator and room temperature. At
both the temperature the formulation was kept for 3 months. Small amount of the sample was
withdrawn at periodic intervals for performing the following tests.
a) Physical appearance
b) In vitro drug release (dissolution)
c) pH of the solution
d) Percentage of drug entrapment.
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RESULTS AND DISCUSSION
DEVELOPMENT OF GLIMEPIRIDE-CYCLODEXTRIN COMPLEXES:
The glimepiride cyclodextrin complexes were prepared by kneading method. 4mg of
glimepiride, 4mg β- cyclodextrin, 20mg poly ethylene glycol, 2mg Tween 80 were taken. The
mixture was heated and 20ml of acetone was added to it. This was then sonicated using Probe
sonicator  set  at  60W of  energy  output  for  90secs.  This  was  further  evaporated  by flash
rotatory evaporator for 60mins.
Formulations with different ratios of polymer were prepared. Several physicochemical
characteristics  of  nanoparticles  like  morphology,  particle  size  determination,  drug release
profile were investigated. Stability of the formulation at various temperatures was evaluated.
DRUG AND POLYMER COMPATIBILITY STUDIES BY FTIR: 73, 74, 75.
Infrared spectroscopy by potassium bromide pellet method was carried out on pure
substance  (glimepiride  and  β-  cyclodextrin  complexes)  seperately  and  their  physical
mixtures.  They are compressed under  15 tonnes pressure in a hydraulic  press to form a
transparent pellet. Then the pellet was scanned from 4000-400 cm-1 in a spectrophotometer.
         To determine any possible molecular interactions between the drug and the
polymer,  the spectrum of physical  mixture was compared with the original  spectra.  FTIR
analysis  measures  the  selective  absorbance  of  light  by  the  viberation  modes  of  specific
chemical bonds in the sample. 
They  are  compressed  under  15  tonnes  pressure  in  a  hydraulic  press  to  form  a
transparent pellet. The pellet was scanned from 4000-400 cm-1 in a spectrophotometer.
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RESULTS AND DISCUSSION
Table 8: IR spectra data for pure drug glimepiride:
 
Table 9: IR spectra data for β- cyclodextrin complexes:
Frequency
cm-1
Groups assigned
            2919 Aliphatic  C-H
stretching
            1702 C=O stretching
            1099 C-N stretching
            In FTIR spectra the peaks of physical mixture was compared with the original
spectra. Same peaks were observed, there is no possible molecular interactions between
the drug and the polymer.
ENTRAPMENT EFFICIENCY OF NANOPARTICLES: 76.
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Frequency cm-1 Groups assigned
          3370 N-H stretching
          3135 Aromatic  C-H
stretching
          2932 C-H  stretching
           1700 C=O stretching
           1115 C-N stretching
RESULTS AND DISCUSSION
The  entrapment  efficiency  of  glimepiride  loaded  nanoparticles  was  prepared  by
kneading method. The formulation CD1 (GMP 4mg, β- CD 4mg, PEG 20mg, tween 80 2mg)
showed entrapment efficiency value of 49%. This is due to the repulsive force between drug
and the polymer.
Increase the cyclodextrin concentration in formulation CD2, (GMP 4mg, β- CD 8mg,
PEG 20mg,  tween 80 2mg) was used. The entrapment value was 56%. The cyclodextrin
concentration was increased to 12, 16 and 20mg in the formulation CD3, CD4, CD5 and
showed the entrapment efficiency value of 60%, 61% and 68%.
There was a steady increased in the entrapment efficiency from 72%, 73%, 83%, 85%
in the formulation CD6, CD7, CD8 and CD9.
The concentration of β- CD was further increased to 40mg in CD10 formulation. PEG
and tween 80 were kept constant in all the formulations. The E.E value showed 94%. This is
due to the high repulsive force between drug and the polymer.
Table 10: Entrapment efficiency formulations with drug and polymer:
INVITRO DRUG RELEASE PROFILE ON NANOPARTICLES:
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S.No
Formulation
code
Drug(mg)    β-
CD(mg)
PEG(mg) Tween80
(mg)
E.E (%)
    1 CD1 4 4 20 2 49±0.14
    2 CD2 4 8 20 2 56±0.11
    3 CD3 4 12 20 2 60±0.08
    4 CD4 4 16 20 2 61±0.12
    5 CD5 4 20 20 2 68±0.09
    6 CD6 4 24 20 2 72±0.17
    7 CD7 4 28 20 2 73±0.12
    8 CD8 4 32 20 2 83±0.17
    9 CD9 4 36 20 2 85±0.08
   10 CD10 4 40 20 2 94±0.05
RESULTS AND DISCUSSION
 The  in  vitro  drug  release  of  glimepiride  nanoparticles  was  carried  out  by
membrane diffusion method. It was carried out for 24hours.
 In all the formulations, pure drug glimepiride 4mg was taken. PEG 20mg and
tween  80  2mg  were  taken  constant  in  all  the  ten  formulations.  The
concentration of β- cyclodextrin was gradually increased in each formulation
to achieve the maximum release rate.
 In  formulation  CD1,  β-CD  4mg  was  used  to  control  the  release  of
Glimepiride. The release at the end oh 24 hours was not found to be 63.1%
only. It is not acceptable criteria of USP limit.
 Hence, in formulation CD2, β-CD concentration was increased to 3mg. The
release rate at the end of 24 hours was found to be 65.6 %.
 To increase the release rate further, β-CD concentration was increased to12,
16,20mg in the formulations CD3, CD4, CD5 respectively. The release rate
was increased to 78.2%, 80.7% and 83.0% respectively.
 Then in formulations CD6, CD7, CD8 and CD9. The concentration of β  –
cyclodextrin was further more increased to 24, 28,  32 and 36mg. Then the
development in the release rate was observed with consequent increase in the
release rate as 85.8%, 88.3%, 90.8% and 93.4%
 For  further  increase  in  the  release  rate,  the  concentration  of  β-CD  was
increased to 40mg in the formulation CD10.The release rate was found to be
maximum. The release rate was 95%.
 Hence CD10 in the optimized formulation among the rest  and formulation
CD10 was chosen for further studies.
Table 11: In vitro drug release for CD1:
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Time
(hrs)
Amount of drug
release (mg)
Cumulative amount of
drug release
Cumulative % drug
release
    1        0.1           02.50           02.50
    2        0.1           02.50          02.50
    3        0.3           07.51          07.55
    4        0.4           10.07          10.07
    5        0.6           15.04          15.12
    6        0.7           17.50          17.65
    7        0.9           22.51          22.70
    8        1.0           25.03          25.22
    9        1.0           25.03          25.22
   10        1.2           30.00          30.27
   11        1.3           32.58          32.80
   12        1.3           32.58          32.80
   13        1.5           37.51          37.85
   14        1.7           42.56          42.90
   15        1.8           45.00          45.42
   16        1.9           47.56          47.95
   17        2.0           50.07          50.47
   18        2.1           52.51          53.00
   19        2.1           52.51          53.00
   20        2.2           55.09          55.52
   21        2.3           57.55          58.05
   22        2.4           60.01          60.57
   23        2.4           60.60          60.57
   24        2.5           62.59          63.10
Fig 3: In vitro drug release for formulation CD1:
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Table 12: In vitro drug release for CD2:
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Fig 4: In vitro drug release for formulation CD2:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1         0.1            02.50        02.50
     2         0.3            07.55        07.55
     3         0.4            10.05        10.07
     4         0.5            12.55        12.68
     5         0.6            15.05        15.12
     6         0.8            20.51        20.17
     7         0.9            22.59        22.78
     8        1.0            25.08        25.22
     9        1.0            25.08        25.22
    10        1.2            30.81        30.27
    11        1.3            32.55        32.81
    12        1.5            37.51        37.85
    13        1.6            40.05        40.37
    14        1.7            42.59        42.98
    15        1.9            47.55        47.95
    16        2.0            50.52        50.47
    17        2.0            50.52        50.47
    18        2.1            52.58        53.29
    19        2.2            55.04        55.52
    20        2.3            57.54        58.05
    21        2.3            57.54        58.05
    22        2.4            60.81        60.57
    23        2.5            62.51        63.18
    24        2.6            65.18        65.62
RESULTS AND DISCUSSION
Table 13: In vitro drug release for CD3:
Fig 5: In vitro drug release for formulation CD3:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1          0.2             05.59          05.02
     2          0.3             07.50           07.55
     3          0.5             12.59           12.69
     4          0.7             17.54           17.65
     5          0.8             20.08           20.17
     6          0.9             22.56           22.78
     7          1.0             25.84           25.22
     8          1.1             27.56           27.75
     9          1.1             27.56           27.75
    10          1.2             30.80           30.27
    11          1.5             37.55           37.85
    12          1.6             40.48           40.37
    13          1.7             42.59           42.95
    14          1.9             47.52           47.95
    15          2.2             55.08           55.52
    16          2.3             57.55           58.05
    17          2.4             60.51           60.57
    18          2.6             65.81           65.62
    19          2.8             70.08           70.67
    20          2.9             72.58           72.57
    21          3.0             75.08           75.72
    22          3.0             75.08           75.72
    23          3.1             77.55           78.25
    24          3.1             77.55           78.25
RESULTS AND DISCUSSION
Table 14: In vitro drug release for CD4:
Fig 6: In vitro drug release for formulation CD4:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1          0.2              05.82         05.02
     2          0.4              10.08         10.07
     3          0.5              12.55         12.65
     4          0.6              15.54         15.12
     5          0.7              17.54         17.65
     6          0.9              22.55         22.79
     7          1.0              25.15         25.22
     8          1.0              25.15         25.22
     9          1.1              27.58         27.75
    10          1.3              32.58         32.85
    11          1.4              35.08         35.32
    12          1.6              40.08         40.37
    13          1.8              45.84         45.42
    14          1.9              47.56         47.95
    15          1.9              47.56         47.95
    16          2.0              50.05         50.47
    17          2.1              52.52         53.08
    18          2.2              55.49         55.52
    19          2.4              60.45         60.57
    20          2.6              65.95         65.62
    21          2.8              70.58         70.67
    22          2.9              72.55         72.57
    23          3.0              75.27         75.72
    24          3.2              80.08         80.77
RESULTS AND DISCUSSION
0 2 4 6 8 10 12 14 16 18 20 22 24
0
10
20
30
40
50
60
70
80
90
time in hrs
cu
m
u
la
ti
v
e
 %
 d
ru
g
 r
e
le
a
se
Table 15: In vitro drug release for CD5:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1          0.3              07.58        07.55
     2         0.5              12.55        12.65
     3         0.7              17.50        17.65
     4         0.8              20.81        20.17
     5         0.9              22.55        22.75
     6         1.0              27.58        27.75
     7         1.2              30.82        30.27
     8         1.4              35.81        35.32
     9         1.5              37.50        37.85
    10         1.7              42.55        42.95
    11         1.8              45.08        45.42
    12         2.0              50.28        50.47
    13         2.0              50.28        50.47
    14         2.2              55.08        55.52
    15         2.4              60.48        60.57
    16         2.5              62.55        63.12
    17         2.5              62.55        63.12
    18         2.6              65.29        65.62
    19         2.8              70.58        70.67
    20         3.0              75.18        75.72
    21         3.1              77.54        78.25
    22         3.2              80.18        80.77
    23         3.3              82.55        83.38
    24         3.3              82.55        83.38
RESULTS AND DISCUSSION
Fig 7: In vitro drug release for formulation CD5:
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Table 16: In vitro drug release for CD6:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1         0.3             07.51         07.55
     2         0.4             10.08        10.07
     3         0.6             15.18        15.12
     4         0.8             20.18        20.17
     5         0.9             22.58        22.75
     6         1.0             25.04        25.22
     7         1.1             27.54        27.75
     8         1.2             30.09        30.27
     9         1.4             35.04        35.32
    10         1.7             42.51        42.94
    11         1.8             45.17        45.42
    12         1.9             47.54        47.95
    13         2.0             50.45        50.47
    14         2.1             52.51        53.20
    15         2.3             57.54        58.05
    16         2.4             60.18        60.57
    17         2.5             62.57        63.15
    18         2.7             67.57        68.15
    19         2.9             72.51        72.57
    20         3.0             75.18        75.72
    21         3.0             75.18        75.72
    22         3.1             77.54        78.25
    23         3.3             82.53        83.35
    24         3.4             85.08        85.82
RESULTS AND DISCUSSION
Fig 8: In vitro drug release for formulation CD6:
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Table 17: In vitro drug release for CD7:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1        0.4           10.28 10.07
     2        0.5           12.58 12.6
     3        0.6           15.08 15.12
     4        0.8           20.58 22.75
     5        0.9           22.58 22.75
     6        1.0           25.85 25.22
     7        1.0           25.08 25.22
     8        1.1           27.54 27.75
     9        1.2           30.08 30.27
    10        1.4           35.81 35.32
    11        1.6           40.18 40.37
    12        1.7           42.54 42.91
    13        1.8           45.18 45.42
    14        1.9           47.58 47.95
    15        2.2           55.14 55.52
    16        2.4           60.18 60.57
    17        2.6           65.18 65.62
    18        2.7           67.54 68.15
    19        2.9           72.53 72.57
    20        3.0           75.18 75.72
    21        3.1           77.58 78.25
    22        3.3           82.57 83.38
    23        3.4           85.08 85.82
    24        3.5           87.58 88.35
RESULTS AND DISCUSSION
Fig 9: In vitro drug release for formulation CD7:
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Table 18: In vitro drug release for CD8:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1        0.4            10.07      10.07
     2        0.6            15.18      15.12
     3        0.7            17.54      17.65
     4        0.8            20.08      20.17
     5        1.0            25.18      25.22
     6        1.1            27.54      27.75
     7        1.3            32.57      32.88
     8        1.4            35.48      35.32
     9        1.6            40.18      40.37
    10        1.7            42.57      42.99
    11        1.8            45.45      45.42
    12        2.0            50.84      50.47
    13        2.3            57.57      58.05
    14        2.5            62.54      63.14
    15        2.6            65.04      65.62
    16        2.7            67.55      68.15
    17        2.9            72.55      72.57
    18        3.0            75.01      75.72
    19        3.0            75.01      75.72
    20        3.1            77.55      78.25
    21        3.3            82.54      83.38
    22        3.4            85.07      85.82
    23       3.5            87.55      88.35
    24        3.6            90.18      90.87
RESULTS AND DISCUSSION
Fig 10: In vitro drug release for formulation CD8:
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Table 19: In vitro drug release for CD9:
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Time
(hrs)
Amount  of
drug  release
(mg)
Cumulative  amount
of drug release
Cumulative  %
drug
release
     1 0.5 12.55 12.6
     2 0.7 17.52 17.65
     3 0.9 22.58 22.78
     4 1.3 32.59 32.81
     5 1.5 37.54 37.85
     6 1.6 40.28 40.37
     7 1.8 45.81 45.42
     8 1.9 47.58 47.95
     9 2.0 50.08 50.47
    10 2.2 55.48 55.52
    11 2.2 55.18 55.52
    12 2.3 57.54 58.05
    13 2.4 60.08 60.57
    14 2.6 65.07 65.62
    15 2.6 65.07 65.62
    16 2.7 67.57 68.15
    17 2.9 72.58 72.57
    18 3.0 75.08 75.72
    19 3.1 77.54 78.25
    20 3.2 80.15 80.77
    21 3.4 85.18 85.82
    22 3.6 90.17 90.87
    23 3.6 90.77 90.87
    24 3.7 92.54 93.41
RESULTS AND DISCUSSION
Fig 11: In vitro drug release for formulation CD9:
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Table 20: In vitro drug release for CD10:
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. Page 68
Time
(hrs)
Amount  of
drug  release
(mg)
% of drug release Cumulative  %
drug
release
     1          0.5              12.55      12.6
     2          0.6              15.18      15.12
     3          0.8              20.18      20.17
     4          0.9              22.54      22.75
     5          1.0              25.87      25.22
     6          1.2              30.17      30.27
     7          1.4              35.17       35.32
     8          1.5              37.57       37.85 
     9          1.7              42.54       42.55
    10          1.9              47.54       47.51
    11          2.1              52.57       52.51
    12          2.2              55.87       55.48
    13          2.5              62.51       62.56
    14          2.6              65.18       65.41
    15          2.8              70.47       70.47
    16          2.8              70.47       70.47
    17          3.0              75.18       75.48
    18          3.2              80.18        80.18
    19          3.2              80.18        80.18
    20          3.3              82.54        82.59
    21          3.5              87.54        87.55
    22          3.6              90.18        90.18
    23          3.7              92.55        92.58
    24          3.8              95.12        95.18
RESULTS AND DISCUSSION
Fig 12: In vitro drug release for formulation CD10:
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Fig 13: Summarized in vitro drug release of nanoparticles formulation (CD1-CD10)
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MORPHOLOGY OF NANOPARTICLES:
The  characteristics  of  CD10  formulation  particle  size  was  studied  by  simple
microscopy. Small amount of the sample was placed in glass slide and viewed through simple
microscope. Image of prepared nanoparticle shows the encapsulation of polymer mixture on
drug particles.
SCANNING ELECTRON MICROSCOPE: 77, 78, 79.
The  surface  characteristics  of  optimized  formulation  (CD10)  particle  size  were
studied by SEM. The SEM image of prepared nanoparticle formulation shows the coating of
polymer mixture on drug particles. The size distribution of nanoparticles indicates a thin and
uniform coating over the drug.
SURFACE CHARGE (ZETA POTENTIAL): 80.
Zeta  potential  of  glimepiride  cyclodextrin  complexes  is  commonly  used  to
characterise the  surface  property of  nanoparticle.  It  reflects  the electrical  potential  of  the
nanoparticle and is influenced by the composition of the particle and the medium in which it
is dispersed.
The  zeta  potential  of  the  formulation  showed  zeta  potential  of  -4.65mV  which
confirmed that the particle of the formulation remains stable.
Zeta potential result shows good and the value is increased due to the fact that the
surface free energy of β- cyclodextrin is increased. The size distribution report by intensity
showed the average size of 170.3 nm.
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RESULTS AND DISCUSSION
STABILITY TESTING OF GLIMEPIRIDE NANOPARTICLES:
The stability studies of the optimized formulation F10 was carried out for 3 months at
40 C, room temperature and 450 C/70% RH. At the time interval of 1 month the nanoparticle
formulation was evaluated for entrapment efficiency. The stability of the formulation was
stable at 40C when compared to room temperature and at 450C/70%RH.
Table 21: Stability studies of nanoparticles:
S.No Storage
condition
Test
parameters 1st month 2nd month 3rd month
   1 40 C pH
Colour
Invitro %
release at 24th hr
   7.4
Clear  and
colourless
    95.11
   7.4
Clear  and
colourless
    95.18
    7.4
Clear  and
colourless
    95.20
   2 Room
temperature
pH
Colour
Invitro %
release at 24th hr
    7.4
Clear  and
colourless
    95
    7.4
Clear  and
colourless
    90.97
    7.4
Clear  and
colourless
    90.16
   3 Acceleration
condition  at
450C/70%RH
pH
Colour
Invitro %
release at 24th hr
    7.3
Clear  and
colourless
    95
    7.3
Clear  and
colourless
    81.66
    7.3
Clear  and
colourless
    80.65
Table 22: In vitro release for optimized formulation CD10 stability study at 40 C:
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 Time
(Hrs)
                                 Cumulative % drug release
1st month (%) 2nd month (%) 3rd month (%)
   1      12.65 12.4 11.01
   2      15.12 15.10 14.96
   3      20.17 19.75 19.54
   4      22.78 22.17 21.09
   5      25.22 25.10 24.85
   6      30.27 29.95 29.56
   7       35.32 35.01 34.12
   8       37.85 36.15 35.97
   9       42.55 42.09 41.68
  10       47.57 46.54 46.09
  11       52.54 51.23 51.02
  12       55.49 54.86 54.58
  13       62.58 62.44 61.96
  14       65.18 64.96 64.34
  15       70.08 69.94 69.54
  16       70.08 69.64 69.54
  17       75.18 74.75 73.65
  18        80.18 79.92 78.25
  19        80.18 79.92 79.43
  20        82.54 81.25 80.24
  21        87.58 87.18 86.18
  22        90.19 89.81 89.51
  23        92.51 91.18 91.10
  24        95.11 95.18 95.20
 
Fig 14: Stability study release data for formulation CD10 after 3 months at 40C:
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Table  23:  In  vitro  data  for  optimized  formulation  CD10  stability  study  at  room
temperature:
 Time
(Hrs)
                                 Cumulative % drug release
1st month (%) 2nd month (%) 3rd month (%)
   1      12.68          01.06          01.04
   2      15.12          08.05          07.05
   3      20.17          11.07          10.95
   4      22.7          16.10          15.60
   5      25.22          17.15          16.45
   6      30.27          19.16          18.56
   7       35.32          26.18          26.08
   8       37.85          29.25          29.17
   9       42.54          34.28          33.85
  10       47.59          35.33          35.53
  11       52.58          40.34          39.44
  12       55.08          42.39          41.59
  13       62.58          46.41          45.31
  14       65.08          48.45          48.25
  15       70.45          56.47          56.17
  16       70.45          58.55          57.55
  17       75.18          62.57          67.97
  18        80.71          67.61          66.81
  19        80.71         70.66         70.15
  20        82.54         73.69         72.59
  21        87.51         75.72         75.18
  22        90.74         77.74         77.54
  23        92.58         83.76         80.76
  24        95.05         90.97         90.16
Fig  15:  Stability  study  release  data  for  formulation  CD10  after 3  months  at  room
temperature:
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Table 24: In vitro data for optimized formulation CD10 stability study at 450C/ 75%RH:
 Time
(Hrs)
                                 Cumulative % drug release
1st month (%) 2nd month (%) 3rd month (%)
   1       12.61          05.0            01.05
   2       15.12          09.04            04.02
   3       20.17         11.08            06.05
   4       22.73         14.10            07.07
   5       25.22         15.13            12.08
   6       30.27         20.14            14.13
   7       35.32         26.19            18.15
   8       37.85         29.25            24.19
   9       42.55         31.28            26.25
  10       47.54         33.30            29.26
  11       52.57         36.32            30.30
  12       55.81         37.35            32.31
  13       62.55         41.36            35.33
  14       65.18         42.40            37.36
  15       70.18         44.41            41.38
  16       70.18         47.43            42.42
  17       75.18         49.45            44.43
  18       80.82         50.48            47.45
  19       8082         55.49            50.48
  20       82.58         56.54            54.51
  21       87.52         62.55            59.55
  22       90.18         65.61            62.60
  23       92.59         77.64            74.63
  24       95.15         81.66            80.65
Fig 16: Stability study release data for formulation CD10 after 3 months at 450C/75%
RH:
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KINETICS OF DRUG RELEASE FOR OPTIMIZED FORMULATION CD10:
The optimized formulation CD10 was introduced into graphical treatment for kinetics
of drug release.
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The  optimized  formulation  CD  of  nanoparticles  is  more  suitable  for  parentral
administration it shows good in the in vitro kinetic study. The zero order plots wee obtained
by plotting cumulative percentage drug release versus time. The regression value is 0.987.
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FIRST ORDER KINETICS OF DRUG RELEASE:
The first  order plot  was made by plotting log time remaining cumulative % drug
release against time. The regression value was found to be    which indicates that drug release
does not follow first order rate kinetics.
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RESULTS AND DISCUSSION
HIGUCH’S PLOT:
Higuchi plot was made by plotting cumulative % drug release against square root of
time. The regression value was found to be 0.951. This indicates that diffusion is one of the
mechanisms of drug release.
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RESULTS AND DISCUSSION
KORSEMEYER PLOT:
The graph was plotted between log cumulative % of drug release and log time. [the
value was found to be 0.992 anomalous (non – Fickian) diffusion. 
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CONCLUSION
SUMMARY AND CONCLUSION
The present study glimepiride nanoparticles aimed to develop a nanoparticulate drug
delivery system using cyclodextrin inclusion complexes.
The polymer enhances the binding of glimepiride nanoparticles in specific or targeted
site  with  sustained  release  of  drug  which  increases  the  therapeutic  efficacy.  These
nanoparticles may also reduce the dose and dose frequency with desired therapeutic response.
The preformulation studies were performed using FTIR. The spectra pure drug and
the formulation were examined. The study revealed the absence of interaction between drug
and the polymer.
All  the batches of nanoparticles (CD1-CD10) were prepared by kneading method.
Formulation was subjected to following evaluation tests which involves;
 Entrapment efficiency
 In vitro drug release studies
 Microscopic determination
 Particle size determination
The entrapment efficiency of the optimized formulation was 94±0.05% and the in vitro drug
release  was  94.89%  after  24  hrs.  It  obeys  zero  order,  follows  diffusion  and  erosion
mechanism  of  release.  Particle  size  determination  by  SEM  shows  the  best  formulation
containing size of 170 nm. Therefore it can target the tissues and has a quick onset of action.
The optimized formulation was examined for zeta potential determination. The formulation
CD10 showed maximum deviation of -4.65 mV which demonstrates that the particles are
separate  and  highly  repelling.  The  repelling  property  was  more  useful  in  decreasing
opsonisation. Further studies are to be carried out to reduce the side effects. 
Therefore, formulated glimepiride nanoparticles can be expected to gain considerable
attention in the treatment of type 2 diabetes mellitus due to its improved therapeutic activity.
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